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Abstract 
 
The purpose of oral toxicity study B in the EU project G-TwYST was to assess the effects of genetically 
modified (GM) maize NK 603, grown both with and without the use of RoundUp, when fed to rats for 
a period of 90 days at incorporation rates of 11% and 33% in the feed. The effects were assessed 
relative to the responses for rats fed the near-isogenic non-GM maize, and the differences were 
compared, using a recently developed method for equivalence testing, to differences between non-
GM feeds obtained in previous studies performed in the EU project GRACE.  
Given tentative settings for regulatory parameters, for a set of 320 comparisons involving body and 
organ weights, haematology and clinical chemistry, equivalence was established in 94% of cases, 
close to the nominal confidence level of the test which was 95%. Equivalence was found to be more 
likely than lack of equivalence in 100% of cases.  
In addition to this primary analysis, the report also contains results for equivalence testing using 
external target effect sizes for a limited set of variables, results for classical statistical analysis of 
differences, graphs of standardised effect sizes such as performed in the GRACE study, results of 
factorial analysis and graphs showing correlations between variables associated with liver or kidney 
damage.   
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1 Introduction 
The purpose of oral toxicity study B in the EU project G-TwYST was to assess the effects of genetically 
modified (GM) maize NK 603, grown both with and without the use of RoundUp, when fed to rats for 
a period of 90 days at incorporation rates of 11% and 33% in the feed. The effects were assessed 
relative to the responses for rats fed the near-isogenic non-GM maize. 
This report describes the results of the statistical analysis of the data from Study B. In principle, the 
statistical analysis was performed according to section 8 of the study plan (Zeljenková and Steinberg 
2015). Deviations from the study plan were as follows: 
• The study plan specified a statistical analysis of data for males and females together, unless 
there were prior biological arguments or statistical indications to analyse males and females 
separately. However, toxicologists preferred separate statistical analysis of males and 
females for all variables, because it was thought that any specific non-target effect might be 
sex-specific. 
• The study plan anticipated pre-specified limits for use in equivalence testing. However, such 
limits could not be established in an early phase of the project. Therefore, an alternative 
method for equivalence testing was developed (van der Voet et al. 2017) and applied. This 
method makes use of historical non-GM data to obtain reference values for acceptable and 
normal variation in the observed variables. For the analysis of the data in G-TwYST, the data 
from non-GM varieties in the preceding GRACE project were available as historical data. 
Target effect sizes for a few variables were recently proposed by Hong et al (2017). Although 
these values have no formal status, equivalence tests were also performed using these effect 
sizes as originally planned. 
The results comparing for each variable each GM dose group to the non-GM control group are 
presented according to four schemes of statistical analysis: 
1. Equivalence tests, following the method developed in the G-TwYST project (van der Voet et 
al, 2017). 
2. For a small number of variables: equivalence tests, based on target effect sizes suggested in 
Hong et al (2017). 
3. Classical tests, in line with OECD Guidance document 116 (2012). 
4. Standardised effect sizes, following the methods used in the GRACE project (Schmidt et al, 
2016, 2017). 
In addition, results from more integrated analyses were obtained: 
5. Factorial analysis, integrating over the five dose group, with main factors GM inclusion rate 
and RoundUp, and the interaction between these two factors. 
6. Correlation analysis, showing co-variation of effects for variables related to the same target 
organ. 
This report is organised as follows. Section 2 describes the data, both the data from the current study 
and the non-GM data from the GRACE studies A-E as used in the equivalence tests. Section 3 
describes data pre-processing procedures, such as summarising the growth and food intakes over 
time, outlier identification and assumptions checking. Section 4 presents the main results according 
to the six schemes of statistical analysis. Section 5 gives a summary and some evaluation of the 
methodology. Appendices to this report are provided as a separate document. 
G-TwYST Study B  Statistical report 
4 
 
2 Data 
2.1 Data in G-TwYST study B 
Study B is a 90-day (sub-chronic) toxicity study in rats fed GM maize NK603. A full description of the 
data that have been measured is given in the study plan (document 632165 B/2016/GLP, Zeljenková 
and Steinberg 2015). There are five feeding groups which are administrated to cages with 2 rats in 
each cage. Experimental units, i.e. cages, are organized in blocks of 5 cages, and the feeding groups 
are randomized within blocks. The design is thus a complete randomized block design with cage as 
the experimental units. There are eight blocks with male rats and eight other blocks with female rats. 
Most of the measurements are on individual animals, only feed intake is measured on the cage level. 
Some specific measurements, notably immunology and cytokines, are only done on a limited number 
of rats. 
The definition of the five feeding groups is given in Table 1. This includes the coding of the blinded 
treatments. In this report the Group labels (Control, NK11-, NK33-, NK11+ and NK33+) will mostly be 
used. 
Table 1 Feeding groups used in study B. 
Factor Levels / Labels 
Treat (blinded) XE XA XC XD XB 
Group Control NK11- NK33- NK11+ NK33+ 
Maize Control NK603 NK603 NK603 NK603 
AmountNK 0 11 33 11 33 
RoundUp No No No Yes Yes 
 
Male and female rats were analysed separately. Since cage is the experimental unit an analysis of 
variance employs cage means with degrees of freedom as in Table 2. The main interest is in the 
difference between each of the four GM maize feeding groups and the control feeding group. 
Table 2 Skeleton analysis of variance for cage means for a single sex. 
Source of variation d.f. 
Block stratum 7 
Block.Cage stratum 
 Group 
 Residual 
 
4 
28 
Total 39 
 
The observed variables in Study B are given in Table 3. 
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Table 3 List of grouped variables with abbreviated names, descriptions and measurement units. 
Grouping is indicated by the headers in the first column. The Grace column indicates 
whether the same variable was measured in the GRACE study. Variables given in red are 
not statistically analysed (see section 4.3.1 for details). 
Weights Description Unit Grace 
Weight 1-14 Body weight at weeks 0, 1 … 13 g/animal X 
Feed 1-13 Feed intake in week 1, 2 … 13 g/cage X 
BodyWeight Body weight at the end of the trial, i.e. at week 13 g/animal X 
growthRate Growth rate fitted to the weight over all weeks  1/week X 
FeedMean Mean of feed intake over 13 weeks g/animal/day X 
Haematology Description Unit Grace 
WBC white blood cells 109/L X 
RBC red blood cells 1012/L X 
HGB haemoglobin g/dL X 
HCT haematocrit % X 
MCV mean cell volume fL X 
MCH mean corpuscular haemoglobin pg X 
MCHC mean corpuscular haemoglobin concentration g/dL X 
PLT platelets 109/L X 
LYMR  relative lymphocytes count % - 
LYMA absolute count of lymphocytes 103/uL X 
diffWBC Description Unit Grace 
Lymphocytes Percentage of lymphocyte cells in 200 cells % X 
Neutrophils Percentage of neutrophil cells in 200 cells % X 
Monocytes Percentage of monocyte cells in 200 cells % X 
Eosinophils Percentage of eosinophil cells in 200 cells % X 
Basophils Percentage of basophil cells in 200 cells % X 
ClinChem Description Unit Grace 
ALP alkaline phosphatase μkat/L X 
ALT alanine aminotransferase μkat/L X 
AST aspartate aminotransferase μkat/L X 
BIL bilirubin μmol/L - 
ALB albumin g/L X 
TP total protein g/L X 
Glu glucose mmol/L X 
CHOL cholesterol mmol/L X 
TAG triglycerides mmol/L X 
Crea creatinine mmol/L X 
Urea urea mmol/L X 
cHGB haemoglobin mg/dL - 
Ca calcium mmol/L X 
Cl chloride mmol/L X 
K potassium mmol/L X 
Na sodium mmol/L X 
P phosphorus mmol/L X 
Urine Description Unit Grace 
uVol Urine Volume ml  
uVolW Urine Volume / bodyweight ml /100g  
uColour Urine Colour (1 – light yellow; 2 – yellow; 3 – dark 
 
-  
uBil bilirubin μmol/L   
uLeu leukocytes leu/uL  
uNit nitrites neg/pos  
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uOsmoll osmolality mOsm  
uProtein total protein g/L   
uGlu glucose mmol/L   
uHemogl haemoglobin ery/uL  
uKeton ketone mmol/L  
upH pH -   
uUrobili urobilinogen μmol/L   
Organs Description; all as percentage of BodyWeight Unit Grace 
Kidney  Percentage weight of kidney % X 
Spleen Percentage weight of spleen % X 
Liver Percentage weight of liver % X 
AdrenGl Percentage weight of adrenal gland % X 
Heart Percentage weight of heart % X 
Thymus Percentage weight of thymus % X 
Testis Percentage weight of testis (males) % X 
Epididymis Percentage weight of epididymis (males) % X 
Uterus Percentage weight of uterus (females) % X 
Ovary Percentage weight of ovary (females) % X 
Brain Percentage weight of brain % X 
Immunology Description Unit Grace 
Granulocytes Phagocytic activity of granulocytes  %  
RespirBurst Respiratory burst of phagocytes %  
Con Proliferative activity of lymphocytes stimulated with mitogen Concanavalin A 
cpm (counts 
per minute)  
PHA Proliferative activity of lymphocytes stimulated with mitogen phytohaemmagglutinin cpm  
PWM Proliferative activity of lymphocytes stimulated  with pokeweed mitogen  cpm  
Medium Proliferative activity of non-stimulated lymphocytes  cpm  
IprConA 
Ratio of proliferative activity of lymphocytes 
 stimulated with Concanavalin A versus 
proliferative activity of non-stimulated lymphocytes 
-  
IprPHA 
Ratio of proliferative activity of lymphocytes 
 stimulated with phytohaemmagglutinin versus 
proliferative activity of non-stimulated lymphocytes 
-  
IprPWM 
Ratio of proliferative activity of lymphocytes 
 stimulated with pokeweed mitogen versus 
proliferative activity of non-stimulated lymphocytes 
-  
Cytokines Description Unit Grace 
IL1a Interleukin 1 alpha pg/mL  
IL1b Interleukin 1 beta pg/mL  
IL2 Interleukin 2 pg/mL  
IL4 Interleukin 4 pg/mL  
IL5 Interleukin 5 pg/mL  
IL6 Interleukin 6 pg/mL  
IL10 Interleukin 10 pg/mL  
IL12p70 Interleukin 12p70 pg/mL  
IL13 Interleukin 13 pg/mL  
IL17A Interleukin 17A pg/mL  
GCSF Granulocyte colony-stimulating factor pg/mL  
GMCSF Granulocyte-macrophage colony-stimulating factor pg/mL  
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TNFa Tumour necrosis factor alpha pg/mL  
IFNg Interferon gamma pg/mL  
CellPhenotype Description Unit Grace 
sp3 Spleen: percentage of cells, not labelled with monoclonal antibody anti-rat CD3 % 
 
sp3_4 
Spleen: percentage of T-cytotoxic lymphocytes, cells 
double labelled with monoclonal antibodies anti-rat 
CD3 and anti-rat CD4 
% 
 
sp3_8 
Spleen: percentage of T-helper lymphocytes, cells 
double labelled with monoclonal antibodies anti-rat 
CD3 and anti-rat CD8 
% 
 
sp3_45 
Spleen: percentage of B- lymphocytes, cells anti-rat 
CD3 antigen negative and anti-rat CD45R antigen 
positive 
% 
 
sp3_161 Spleen: percentage of NK-cells, cells anti-rat CD3 antigen negative and anti-rat CD161 antigen positive  % 
 
ln3 Lymph node: percentage of cells, not labelled with monoclonal antibody anti-rat CD3 % 
 
ln3_4 
Lymph node: percentage of T-cytotoxic lymphocytes, 
cells double labelled with monoclonal antibodies anti-
rat CD3 and anti-rat CD4 
% 
 
ln3_8 
Lymph node: percentage of T-helper lymphocytes, 
cells double labelled with monoclonal antibodies anti-
rat CD3 and anti-rat CD8 
% 
 
ln3_45 
Lymph node: percentage of B- lymphocytes, cells anti-
rat CD3 antigen negative and anti-rat CD45R antigen 
positive 
% 
 
ty3 Thymus: percentage of cells, not labelled with monoclonal antibody anti-rat CD3 % 
 
ty3_4 
Thymus: percentage of T-cytotoxic lymphocytes, cells 
double labelled with monoclonal antibodies anti-rat 
CD3 and anti-rat CD4 
% 
 
ty3_8 
Thymus: percentage of T-helper lymphocytes, cells 
double labelled with monoclonal antibodies anti-rat 
CD3 and anti-rat CD8 
% 
 
Hormone Description Unit Grace 
Testosteron Testosteron (males) ng/ml  
betaEstr 17β – Estradiol (females) pg/ml  
T3 Triiodothyronine hormone nmol/L  
T4 Thyroxine hormone nmol/L  
eCycle Description (females) Unit Grace 
Cycle1 Duration of 1st oestrous cycle (missing = unfinished) days  
Cycle2 Duration of 2nd oestrous cycle (missing = unfinished) days  
Regular Number of regular cycles out of 2 cycles count  
Irregular Number of irregular cycles out of 2 cycles count  
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The variables in Table 3 exclude the following measurements in comparison to the study plan: 
• Histopathological data. Reason: these were excluded from this statistical analysis in the study 
plan, and will be separately reported by the histopathological expert in the G-TwYST project. 
• Periodic health status observations: morbidity, mortality, clinical signs. Rats were inspected 
twice daily for evidence of reaction to treatment or ill-health. No deviations from normal 
findings  were observed in experimental groups and control group of rats, except for 2 
animals: (1) male animal number 41 (feeding group NK33-) was euthanized in week 7 
following paresis of hind limbs, and (2) female animal number (control feeding group) had 
oedema on the front left  limb caused mechanically by strangulation on the lid; it is assumed 
that this is not connected to the experiment. 
• Total and anti-maize/CP4 EPSPS specific antibody levels (IgG, IgM, IgE). These were not 
determined because there is no commercially available ELISA kit to do so. To be able to 
develop a new ELISA test system, it would have been necessary to have the purified CP4 
EPSPS protein, and there was no trustful source that was independent of any plant 
biotechnology company. 
• Organ weights: sternum with bone marrow, thyroid, parathyroid. These were not 
determined and this is in line with the OECD Test Guideline 408, which does not foresee such 
measurements. These measurement were erroneously included in the original study plan.  
All variables that are also observed in the GRACE study are statistically analysed. Some of the other 
variables are not statistically analysed e.g. because all the observed values are identical; see section 
4.3.1 for details. All variables were transformed to the natural logarithmic scale and then averaged to 
the cage level. This implies that, rather than looking at differences between feeding group means, 
ratios between the GM feeds and the Control feed are of interest. Only pH as measured in urine was 
not log transformed because the pH is already measured on the log scale. 
2.2 Reference data in GRACE studies 
Data from the GRACE project are used as historic data to set equivalence limits. These data have 
been analysed before as part of the GRACE project (Schmidt and Schmidtke 2014, Schmidt et al 
2015ab, 2016, 2017, Zeljenková et al 2014, 2016). Note that in the GRACE studies a completely 
randomized design, i.e. without blocking, was used. The GRACE data were retrieved from the Cadima 
website (https://www.cadima.info) at 29-11-2016. In GRACE five studies were conducted with 
several control (or reference) feeds as given in Table 4, see Schmidt et al (2017).  
Table 4 Feeds which were used in the five GRACE studies with reference feeds in bold. 
GRACE Study Control 11% GMO 33% GMO 33% Conv-1 33% Conv-2 
A DKC6666 DKC6667-YG-11 DKC6667-YG-33 PR33W82 SY-NEPAL 
B PR32T16 PR33D48-11 PR33D48-33 PR32T83 DKC6815 
C DKC6666 DKC6667-YG-11 DKC6667-YG-33 - SY-NEPAL 
D DKC6666 DKC6667-YG-11 DKC6667-YG-33 - - 
E PR32T16 PR33D48-11 PR33D48-33 - - 
 
In studies D and E only a single reference feed was used and, since the equivalence analysis corrects 
for differences between studies, these studies do not contribute to the between reference variation. 
In studies A, B and C, the reference feeds DKC6666 and SY-NEPAL were replicated. The degrees of 
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freedom associated with the between reference feeds variance therefore equals 4. The degrees of 
freedom associated with the residual (between cages) variance varies between 50 and 78 since not 
all measurements were done on all rats in every study.  
We re-analysed the GRACE data to enable a comparison with the G-TwYST data. This re-analysis is 
different from the analysis in the GRACE reports in the following ways: 
• For the re-analysis all variables were transformed to the natural logarithmic scale and then 
averaged to the cage level; the thus obtained cage means were used in the statistical analysis; 
• the exponential growth model (see section 3.1) was fitted to the weights observed in GRACE to 
obtain an estimate of the growth rate 𝛾𝛾; 
• The sum of the weights of organ pairs was analysed rather than the left and right organs; 
• outliers were identified by applying Grubbs’ outlier test at the 1% level on residuals of a 
one-way ANOVA which is conducted separately for each study. These outliers were set to 
missing. 
Details of the re-analysis are given in Appendix 8. In Table 3 it is indicated which G-TwYST variables 
have also been measured in the GRACE studies. 
3 Data pre-processing 
The initial data pre-processing is described in Appendix 1, which resulted in two Excel data files with 
combined data: one for male rats and one for female rats. 
3.1 Growth curves and feed intake 
For each individual rat an exponential growth curve 𝐴𝐴 + 𝐵𝐵 𝑅𝑅𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊 was fitted to the observed weights. 
A re-parameterization of this curve is given by 𝐴𝐴 + 𝐵𝐵 exp(−𝛾𝛾 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊) with the growth rate 𝛾𝛾 defined 
by 𝛾𝛾 = − log(𝑅𝑅). In Appendix 2 the observed weights are graphically displayed along with the fitted 
curve and, in the bottom right corner, the resulting estimate of the growth rate 𝛾𝛾. In case an absolute 
standardized residual is larger than 3, the accompanying weight is set to missing and the curve is 
fitted again. Such weight values, the re-estimated growth curve and the re-estimated growth rate 𝛾𝛾 
are given in red in Appendix 2. This results in two sets of parameters which are both given in the 
combined Excel data files. Note that only when there are standardized residuals larger than 3 the two 
sets of parameters are different. SZU remarked on the weights with large residuals that : “Weights 
were checked again, no wrong values (no typing errors) were indicated. Explanation for “outliers” 
might be: loss of appetite of particular rat, fighting between animals, irregular stool etc”. It was 
therefore decided to keep the weights with the large residuals. Note that in general the exponential 
curve fits very well and it is therefore decided to only analyse the final weight observed after week 
13, further called BodyWeight, and the estimated growth rate 𝛾𝛾, further called growthRate. 
The mean weight for each feeding group is given in Figure 1, while the mean weight gain per day per 
animal in each week is given in Figure 2. Feed consumption for each cage in units g/animal/day is 
graphically depicted in Appendix 3. The mean feed consumption for each feeding group is given in 
Figure 3.  
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Figure 1 Mean body weights versus week for each feeding group for male rats (left) and for 
female rats (right). 
 
 
Figure 2 Mean body weights gain (g/day/animal) versus week for each feeding group for male 
rats (left) and for female rats (right). 
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Figure 3 Mean feed consumption (g/day/animal) versus week for each feeding group for male 
rats (left) and for female rats (right). 
3.2 Outliers and checking of ANOVA assumptions 
The cage means, after log transformation, for each observed variable are statistically analysed by 
means of an analysis of variance using the model “Block + Group” according to the randomized block 
design. Grubbs’ outlier test at the 1% level was applied to the residuals to detect outliers. This 
resulted in six outliers which are depicted by the solid symbols in Figure 4. Table 5 lists the outliers 
along with the two values that make up the outlying cage mean on the log scale. Only the bold values 
are considered to be outliers because they represent rather unusual values. The individual values for 
Lymphocytes and for Neutrophils are not very unusual; they are only picked up by Grubbs’ outlier 
test because the mean is somewhat unusual. Note that Lymphocytes and Neutrophils are correlated 
because the sum of the WBC values is 200. This implies that e.g. an unusual large Lymphocytes count 
for an individual must be accompanied with a smaller Neutrophils count, such that the sum of the 
WBC values remains 200 for that individual. 
The outlying values in Table 5 were presented to SZU who remarked that “Male HGB – repeated 
measurements, no technical problems, Differential white blood cell count – % Lymphocytes, 
neutrophils animals No- 53,54 – method – light microscopy – values checked again, no technical 
problems detected”. SZU did not comment on the bold values for Liver (animal 37), Brain (animals 31 
and 73). So given that there were no technical problems with the outliers in Table 5, the potential 
outliers were presented to the toxicological expert and G-TwYST coordinator (Pablo Steinberg, Max 
Rubner Institut) who confirmed the choice of outliers.  
Outlier summary: in addition to the values that were set to missing because there were technical 
problems, see Appendix 2, the bold values in Table 5 were also set to missing. 
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Figure 4 Residuals along the y-axis versus fitted values along the x-axis resulting from an analysis 
of variance on log transformed cage means. Solid symbols denote outliers found by 
Grubbs’ outlier test at the 1% level applied to the residuals. 
Table 5 Cage and animal numbers for which Grubbs’ outlier test is significant at the 1% level 
along with the two values that make up the cage mean. Only the bold values are finally 
considered to be outliers. 
Male/Female Variable Cage Animal Log-Value Value 
Male HGB 7 13 2.70 14.9 
Male HGB 7 14 2.43 11.4 
Male Liver 19 37 1.24 3.462 
Male Liver 19 38 0.90 2.471 
Male Brain 16 31 -1.20 0.301 
Male Brain 16 32 -0.85 0.429 
Male Lymphocytes 27 53 4.71 111 
Male Lymphocytes 27 54 4.76 117 
Male Neutrophils 27 53 4.38 80 
Male Neutrophils 27 54 4.34 77 
Female Brain 73 159 -0.12 0.885 
Female Brain 73 160 -0.73 0.480 
 
Without these outliers cage means on the original scale are given in Appendix 4, while cage means 
after a log transformation of the individual data are given in Appendix 5. Normal probability plots of 
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the ANOVA residuals, of an analysis on cage means after log transformation, are given in Appendix 6. 
To aid interpretation a 99% envelope is added to the probability plots, such that only values outside 
the envelop might be suspicious. Appendix 7 gives plots of residuals versus fitted values after the 
same analysis of variance. These residual plots are generally satisfactory implying that the ANOVA 
assumptions, homogeneity of variance and less importantly normality, are generally fulfilled. 
3.3 Summary tables  
Summary tables, on the original non-transformed scale, of number of observations, means, standard 
deviations and coefficients of variation (%), classified by the feeding groups, are given in Table 6 for 
males and in Table 7 for females. These tables were obtained by first calculating cage means and 
then calculating the summary statistics. The number of cages per feeding group is generally 8, except 
for the Immunology variables with 5 cages, the Cytokine variables with 5 cages for males and 3 cages 
for females, the CellPhenotype variables with 5 cages and the Hormone data with 6 cages for males 
and 8 cages for females. 
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Table 6 Summary statistics for male rats classified by the feeding groups: number of cages (N), means (Mean), standard deviations (Sd) and 
coefficients of variation (CV). The summary statistics are obtained from cage means. 
Weights Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
BodyWeight 8 440 29.8 6.8 8 462 38.6 8.4 8 449 29.0 6.5 8 435 24.8 5.7 8 458 49.2 10.7 
growthRate 8 0.14 0.025 17.0 8 0.14 0.016 12.0 8 0.13 0.027 20.4 8 0.15 0.034 23.4 8 0.14 0.017 11.9 
FeedMean 8 19.6 1.34 6.8 8 20.0 1.86 9.3 8 20.0 1.04 5.2 8 18.5 0.61 3.3 8 19.6 1.88 9.6 
Haematology Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
WBC 8 9.10 1.92 21.1 8 8.85 1.58 17.8 8 9.42 1.63 17.3 8 9.75 1.22 12.5 8 9.57 1.04 10.9 
RBC 8 7.79 0.30 3.8 8 7.77 0.44 5.6 8 7.77 0.27 3.4 8 7.67 0.35 4.6 8 7.83 0.20 2.6 
HGB 8 14.6 0.41 2.8 8 14.7 0.29 2.0 8 14.7 0.44 3.0 8 14.4 0.55 3.8 8 14.8 0.18 1.2 
HCT 8 42.4 1.21 2.8 8 42.8 1.96 4.6 8 43.0 1.40 3.3 8 42.4 1.60 3.8 8 43.2 0.84 2.0 
MCV 8 54.4 1.07 2.0 8 55.2 1.44 2.6 8 55.4 1.16 2.1 8 55.4 1.38 2.5 8 55.1 0.63 1.1 
MCH 8 18.8 0.46 2.5 8 18.7 0.52 2.8 8 19.0 0.69 3.6 8 18.8 0.78 4.2 8 19.0 0.45 2.4 
MCHC 8 34.6 0.28 0.8 8 33.9 0.94 2.8 8 34.2 0.78 2.3 8 33.9 0.59 1.7 8 34.4 0.76 2.2 
PLT 8 842 75 8.9 8 792 120 15.1 8 862 125 14.5 8 851 83 9.7 8 847 115 13.6 
LYMR 8 73.0 3.74 5.1 8 72.5 4.97 6.9 8 70.9 5.89 8.3 8 72.0 3.41 4.7 8 73.4 5.06 6.9 
LYMA 8 6.64 1.55 23.3 8 6.42 1.24 19.3 8 6.68 1.34 20.0 8 7.00 0.70 10.0 8 7.04 1.09 15.4 
diffWBC Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
Lymphocytes 8 71.4 6.45 9.0 8 68.1 6.48 9.5 8 65.8 5.86 8.9 8 69.8 6.53 9.4 8 70.6 6.28 8.9 
Neutrophils 8 25.7 6.58 25.6 8 28.8 7.01 24.3 8 30.5 5.17 16.9 8 26.8 6.83 25.5 8 26.4 6.60 25.0 
Monocytes 8 1.50 0.46 30.9 8 1.66 0.44 26.7 8 1.78 0.92 51.7 8 1.53 0.41 26.8 8 1.31 0.42 31.8 
Eosinophils 8 1.44 0.58 40.3 8 1.41 0.72 51.1 8 1.84 1.32 71.7 8 1.91 0.90 47.0 8 1.72 0.78 45.6 
ClinChem Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
ALP 8 1.25 0.14 11.3 8 1.28 0.18 13.9 8 1.27 0.14 10.7 8 1.25 0.13 10.2 8 1.44 0.19 13.2 
ALT 8 0.56 0.040 7.1 8 0.57 0.061 10.6 8 0.55 0.077 13.9 8 0.50 0.058 11.5 8 0.56 0.080 14.3 
AST 8 2.40 0.60 24.9 8 2.30 0.47 20.6 8 2.23 0.36 16.2 8 2.12 0.38 17.8 8 2.22 0.45 20.3 
BIL 8 7.30 1.97 27.0 8 7.08 0.98 13.8 8 6.92 0.42 6.1 8 7.16 0.82 11.4 8 6.48 0.34 5.3 
ALB 8 36.4 0.81 2.2 8 36.6 1.77 4.8 8 36.9 0.79 2.1 8 37.8 0.99 2.6 8 36.4 1.30 3.6 
TP 8 64.4 1.13 1.7 8 65.1 2.32 3.6 8 65.0 1.08 1.7 8 66.2 1.66 2.5 8 64.6 1.36 2.1 
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Glu 8 5.38 0.85 15.8 8 5.34 0.82 15.3 8 5.02 0.69 13.7 8 5.15 0.36 6.9 8 5.49 0.53 9.6 
CHOL 8 2.05 0.23 11.2 8 2.01 0.27 13.5 8 2.02 0.22 10.8 8 1.94 0.19 10.0 8 2.04 0.17 8.5 
TAG 8 1.02 0.25 24.6 8 1.10 0.14 12.8 8 1.05 0.33 31.3 8 1.03 0.31 30.5 8 1.09 0.39 35.9 
Crea 8 40.1 2.09 5.2 8 41.5 4.78 11.5 8 40.8 3.61 8.8 8 43.8 4.66 10.6 8 41.9 4.15 9.9 
Urea 8 5.13 0.32 6.3 8 4.90 0.55 11.2 8 4.99 0.28 5.6 8 4.88 0.43 8.9 8 4.96 0.50 10.0 
cHGB 8 69.7 46.1 66.1 8 61.1 20.6 33.7 8 58.4 12.8 21.8 8 52.6 15.5 29.5 8 49.4 13.5 27.4 
Ca 8 2.40 0.040 1.7 8 2.40 0.030 1.2 8 2.41 0.056 2.3 8 2.41 0.045 1.9 8 2.39 0.036 1.5 
Cl 8 102 1.33 1.3 8 102 1.19 1.2 8 102 1.03 1.0 8 102 0.70 0.7 8 102 1.22 1.2 
K 8 4.99 0.23 4.5 8 5.09 0.37 7.2 8 5.25 0.20 3.9 8 5.22 0.31 5.9 8 5.11 0.24 4.8 
Na 8 145 1.65 1.1 8 145 1.46 1.0 8 145 1.16 0.8 8 146 1.12 0.8 8 145 1.39 1.0 
P 8 2.37 0.31 13.1 8 2.44 0.19 7.9 8 2.50 0.15 6.1 8 2.41 0.16 6.5 8 2.31 0.18 7.7 
Urine Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
uVol 8 19.2 3.58 18.6 8 19.1 5.53 28.9 8 22.3 7.15 32.0 8 21.1 8.59 40.7 8 19.2 5.09 26.5 
uVolW 8 4.59 0.95 20.7 8 4.31 1.16 26.9 8 5.17 1.69 32.6 8 5.05 2.01 39.7 8 4.39 1.23 28.1 
uLeu 8 28.1 35.8 127.4 8 20.3 13.3 65.3 8 31.2 34.1 109.0 8 26.6 35.6 134.1 8 18.8 9.4 50.4 
uOsmoll 8 489 148 30.2 8 474 94 19.9 8 448 108 24.2 8 455 139 30.5 8 480 90 18.8 
uKeton 8 0.42 0.31 73.9 8 0.78 0.41 52.5 8 0.75 0.93 123.4 8 0.53 0.65 121.8 8 0.31 0.55 175.0 
upH 8 7.12 0.30 4.2 8 7.00 0.40 5.7 8 6.88 0.13 1.9 8 6.94 0.32 4.6 8 6.75 0.19 2.8 
Organs Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
Kidney 8 0.52 0.038 7.2 8 0.52 0.028 5.4 8 0.54 0.029 5.4 8 0.55 0.038 6.9 8 0.52 0.041 7.9 
Spleen 8 0.18 0.015 8.2 8 0.19 0.010 5.6 8 0.18 0.016 9.3 8 0.19 0.015 7.8 8 0.18 0.015 8.1 
Liver 8 2.16 0.10 4.7 8 2.19 0.13 6.0 8 2.24 0.13 5.6 8 2.24 0.10 4.5 8 2.17 0.04 1.8 
AdrenGl 8 0.014 0.0013 9.1 8 0.013 0.0020 15.4 8 0.013 0.0015 11.3 8 0.013 0.0015 11.6 8 0.013 0.0014 11.0 
Heart 8 0.23 0.007 2.8 8 0.24 0.009 3.6 8 0.24 0.014 5.9 8 0.24 0.015 6.2 8 0.23 0.013 5.7 
Thymus 8 0.09 0.012 13.7 8 0.10 0.017 17.4 8 0.10 0.017 17.5 8 0.10 0.018 17.7 8 0.10 0.017 17.3 
Testis 8 0.81 0.084 10.3 8 0.80 0.054 6.8 8 0.82 0.038 4.6 8 0.83 0.054 6.5 8 0.81 0.063 7.8 
Epididymis 8 0.27 0.024 8.9 8 0.26 0.011 4.3 8 0.28 0.020 7.1 8 0.27 0.016 5.9 8 0.27 0.030 11.0 
Brain 8 0.49 0.041 8.4 8 0.48 0.034 7.0 8 0.51 0.021 4.1 8 0.51 0.031 6.1 8 0.49 0.054 11.0 
Immunology Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
Granulocytes 5 73.8 13.0 17.7 5 77.5 9.6 12.4 5 73.6 12.3 16.8 5 73.7 14.3 19.3 5 73.5 11.8 16.1 
RespirBurst 5 64.4 12.6 19.6 5 66.3 9.9 14.9 5 60.1 11.8 19.6 5 60.6 15.7 26.0 5 63.2 9.4 14.8 
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Con 5 77166 21348 27.7 5 78118 16358 20.9 5 70681 15091 21.4 5 73844 16697 22.6 5 83659 17987 21.5 
PHA 5 50436 17825 35.3 5 51083 6848 13.4 5 50736 10519 20.7 5 47416 9575 20.2 5 53347 7981 15.0 
PWM 5 25656 15280 59.6 5 36631 11884 32.4 5 25415 14163 55.7 5 25404 10910 42.9 5 46487 29478 63.4 
Medium 5 2370 902 38.1 5 2324 554 23.9 5 1944 601 30.9 5 1812 242 13.3 5 3003 1407 46.9 
IprConA 5 34.8 8.7 25.0 5 37.4 7.4 19.7 5 40.1 6.1 15.2 5 41.5 14.2 34.1 5 34.7 15.0 43.3 
IprPHA 5 21.8 2.30 10.5 5 26.6 4.79 18.0 5 28.2 2.75 9.7 5 27.2 9.58 35.2 5 21.8 9.36 42.9 
IprPWM 5 10.5 3.04 29.0 5 15.3 3.30 21.6 5 12.7 3.36 26.4 5 13.9 5.69 40.8 5 15.1 4.55 30.0 
Cytokines Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
IL2 5 4082 936 22.9 5 5378 496 9.2 5 4499 658 14.6 5 4477 960 21.4 5 5501 853 15.5 
IL4 5 28.7 24.2 84.4 5 14.6 5.1 34.9 5 10.9 0.7 6.9 5 11.3 1.7 15.3 5 14.1 2.0 14.2 
IL10 5 10265 8214 80.0 5 9151 7329 80.1 5 3256 1579 48.5 5 3677 3005 81.7 5 13753 13026 94.7 
IL17A 5 184 121 66.0 5 146 47 32.6 5 119 48 39.9 5 98 46 46.7 5 198 118 59.4 
TNFa 5 17.9 7.25 40.5 5 25.1 1.74 6.9 5 17.3 2.92 16.9 5 19.2 5.85 30.4 5 26.0 7.08 27.2 
IFNg 5 14401 2655 18.4 5 19549 4549 23.3 5 12162 1740 14.3 5 13601 3607 26.5 5 16342 3902 23.9 
CellPhenotype Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
sp3 5 36.0 5.20 14.4 5 41.7 6.15 14.8 5 41.0 8.66 21.1 5 43.8 4.37 10.0 5 43.0 6.35 14.8 
sp3_4 5 21.4 3.84 17.9 5 24.2 5.14 21.2 5 26.2 6.70 25.6 5 25.6 4.03 15.7 5 26.4 6.25 23.7 
sp3_8 5 14.7 3.05 20.7 5 17.1 2.30 13.4 5 14.9 4.08 27.3 5 18.1 1.42 7.9 5 16.5 1.96 11.9 
sp3_45 5 24.9 1.07 4.3 5 25.6 0.48 1.9 4 24.7 1.35 5.5 5 24.6 1.34 5.4 5 25.2 0.72 2.9 
sp3_161 5 13.6 1.15 8.4 5 13.1 0.76 5.8 4 13.8 1.00 7.3 5 13.5 0.86 6.4 5 12.5 0.71 5.7 
ln3 5 57.8 4.0 7.0 5 59.2 3.9 6.6 5 53.9 11.3 20.9 5 52.7 12.6 23.9 5 54.6 10.5 19.2 
ln3_4 5 42.7 3.1 7.2 5 41.1 2.1 5.0 5 39.5 9.4 23.7 5 37.4 10.7 28.6 5 39.5 9.6 24.2 
ln3_8 5 15.5 1.31 8.5 5 17.9 2.06 11.5 5 15.0 1.95 13.0 5 16.2 2.68 16.5 5 15.6 1.21 7.8 
ln3_45 5 34.5 8.1 23.4 5 29.3 9.3 31.9 5 29.1 7.8 26.8 5 34.0 11.8 34.5 5 30.8 8.2 26.5 
ty3 5 18.4 4.66 25.3 5 18.7 3.72 20.0 5 19.3 2.40 12.5 5 20.0 2.27 11.4 5 20.2 2.94 14.5 
ty3_4 5 14.2 3.17 22.4 5 14.4 2.60 18.1 5 15.1 2.38 15.7 5 15.5 1.40 9.1 5 15.9 2.27 14.3 
ty3_8 5 7.93 1.71 21.6 5 8.39 1.98 23.6 5 8.24 0.68 8.3 5 8.35 1.06 12.7 5 9.00 1.62 18.0 
Hormone Control NK11- NK33- NK11+ NK33+ 
Male N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
Testosteron 6 2.58 0.88 34.3 6 2.78 1.64 59.1 6 1.97 1.12 56.6 6 3.03 1.93 63.7 6 2.17 0.56 25.6 
T3 6 0.75 0.06 8.1 6 0.82 0.14 16.7 6 0.74 0.09 12.1 6 0.75 0.09 12.6 6 0.81 0.08 10.0 
T4 6 55.2 4.74 8.6 6 54.0 5.40 10.0 6 48.7 3.65 7.5 6 55.1 3.77 6.8 6 53.4 5.29 9.9 
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Table 7 Summary statistics for female rats classified by the feeding groups: number of cages (N), means (Mean), standard deviations (Sd) and 
coefficients of variation (CV). The summary statistics are obtained from cage means. 
Weights Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
BodyWeight 8 245 17.2 7.0 8 242 18.7 7.7 8 249 14.8 5.9 8 247 13.6 5.5 8 252 12.4 4.9 
growthRate 8 0.12 0.032 26.5 8 0.16 0.056 35.5 8 0.15 0.038 24.8 8 0.15 0.047 30.6 8 0.18 0.023 12.8 
FeedMean 8 14.0 1.01 7.2 8 12.8 1.51 11.7 8 13.9 1.17 8.4 8 13.6 0.58 4.2 8 14.0 0.92 6.5 
Haematology Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
WBC 8 5.52 1.48 26.7 8 5.37 0.97 18.0 8 6.06 1.16 19.2 8 4.86 0.70 14.4 8 5.43 1.26 23.3 
RBC 8 6.73 0.22 3.3 8 6.72 0.55 8.2 8 6.87 0.17 2.5 8 6.81 0.50 7.3 8 6.66 0.30 4.5 
HGB 8 13.7 0.45 3.3 8 13.6 1.03 7.6 8 14.1 0.18 1.3 8 13.8 0.81 5.9 8 13.6 0.65 4.8 
HCT 8 39.4 1.09 2.8 8 39.1 3.29 8.4 8 40.5 0.95 2.3 8 39.9 2.57 6.4 8 39.6 1.81 4.6 
MCV 8 58.7 1.40 2.4 8 58.2 1.79 3.1 8 59.1 1.03 1.8 8 58.7 1.63 2.8 8 59.6 1.32 2.2 
MCH 8 20.4 0.69 3.4 8 20.2 0.54 2.7 8 20.6 0.44 2.1 8 20.4 0.84 4.1 8 20.4 0.62 3.0 
MCHC 8 34.8 0.83 2.4 8 34.7 0.75 2.2 8 34.8 0.64 1.8 8 34.7 0.93 2.7 8 34.3 0.47 1.4 
PLT 8 902 113 12.6 8 825 144 17.5 8 901 91 10.1 8 813 100 12.3 8 904 94 10.4 
LYMR 8 75.2 5.81 7.7 8 75.1 3.52 4.7 8 77.5 3.52 4.5 8 76.6 4.92 6.4 8 77.1 4.96 6.4 
LYMA 8 4.22 1.37 32.4 8 4.04 0.69 17.2 8 4.69 0.91 19.4 8 3.71 0.69 18.5 8 4.15 0.97 23.4 
diffWBC Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
Lymphocytes 8 69.2 5.98 8.6 8 69.5 6.24 9.0 8 70.4 3.79 5.4 8 71.9 5.15 7.2 8 71.1 4.08 5.7 
Neutrophils 8 28.1 4.73 16.8 8 28.5 5.76 20.2 8 26.8 4.46 16.6 8 26.1 5.02 19.2 8 26.1 4.18 16.1 
Monocytes 8 1.53 0.76 49.7 8 1.12 0.65 58.2 8 1.44 0.83 57.9 8 1.12 0.38 33.6 8 1.25 0.57 45.4 
Eosinophils 8 1.16 1.20 104.0 8 0.91 0.71 77.9 8 1.31 0.94 71.8 8 0.88 1.03 117.3 8 1.56 0.98 62.7 
ClinChem Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
ALP 8 0.58 0.14 23.3 8 0.58 0.06 9.6 8 0.65 0.07 10.0 8 0.58 0.07 12.1 8 0.58 0.10 18.1 
ALT 8 0.47 0.06 12.9 8 0.42 0.04 10.3 8 0.53 0.12 23.0 8 0.45 0.13 29.6 8 0.42 0.08 19.1 
AST 8 2.30 0.67 29.0 8 2.22 0.34 15.5 8 2.33 0.25 11.0 8 2.21 0.53 24.1 8 2.37 0.44 18.7 
BIL 8 7.57 0.97 12.8 8 7.11 0.50 7.1 8 8.13 1.12 13.8 8 7.84 0.97 12.4 8 8.51 2.06 24.2 
ALB 8 42.5 3.53 8.3 8 41.5 2.48 6.0 8 44.6 2.71 6.1 8 44.1 2.64 6.0 8 43.9 2.84 6.5 
TP 8 68.7 3.38 4.9 8 67.2 2.90 4.3 8 71.0 2.55 3.6 8 70.9 2.41 3.4 8 70.5 2.97 4.2 
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Glu 8 5.19 0.35 6.8 8 5.12 1.18 23.1 8 4.40 0.68 15.4 8 5.05 1.12 22.2 8 5.62 1.03 18.3 
CHOL 8 1.91 0.21 11.0 8 2.05 0.28 13.9 8 2.01 0.28 14.0 8 2.00 0.25 12.3 8 1.99 0.34 16.9 
TAG 8 0.52 0.13 24.7 8 0.62 0.20 31.9 8 0.65 0.09 13.4 8 0.60 0.12 19.6 8 0.57 0.09 15.1 
Crea 8 40.9 2.43 5.9 8 42.0 2.84 6.8 8 42.9 3.98 9.3 8 40.8 5.06 12.4 8 41.9 5.67 13.5 
Urea 8 5.86 0.35 6.0 8 5.94 0.85 14.4 8 5.32 0.67 12.6 8 5.29 0.64 12.1 8 5.59 0.57 10.2 
cHGB 8 41.8 22.2 53.2 8 39.8 9.7 24.4 8 49.5 19.0 38.4 8 49.3 24.1 48.9 8 56.4 31.9 56.6 
Ca 8 2.47 0.070 2.8 8 2.45 0.035 1.4 8 2.49 0.040 1.6 8 2.50 0.053 2.1 8 2.49 0.049 2.0 
Cl 8 102 1.03 1.0 8 102 1.54 1.5 8 101 1.06 1.1 8 102 1.15 1.1 8 102 1.88 1.8 
K 8 4.45 0.22 4.8 8 4.46 0.20 4.6 8 4.52 0.29 6.4 8 4.54 0.21 4.7 8 4.70 0.33 7.0 
Na 8 145 1.94 1.3 8 144 1.22 0.8 8 145 1.16 0.8 8 145 1.79 1.2 8 145 2.68 1.9 
P 8 2.04 0.23 11.3 8 1.96 0.23 11.7 8 2.15 0.36 16.8 8 1.93 0.21 11.1 8 1.96 0.22 11.4 
Urine Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
uVol 8 17.1 4.23 24.7 8 17.1 4.52 26.5 8 16.8 7.06 42.2 8 16.7 6.55 39.2 8 13.6 2.99 22.1 
uVolW 8 7.42 1.84 24.8 8 7.49 2.05 27.3 8 7.09 3.00 42.3 8 7.13 2.93 41.1 8 5.70 1.45 25.5 
uLeu 8 10.9 10.4 95.4 8 7.8 9.3 119.0 8 6.2 9.4 151.2 8 20.3 24.0 118.3 8 10.9 17.0 155.0 
uOsmoll 8 413 112 27.2 8 417 104 25.0 8 435 123 28.2 8 414 128 31.0 8 427 63 14.7 
uKeton 8 0.16 0.19 119.0 8 0.03 0.09 282.8 8 0.16 0.27 169.7 8 0.03 0.09 282.8 8 0.00 0.00 - 
upH 8 6.62 0.27 4.0 8 6.44 0.29 4.5 8 6.50 0.23 3.6 8 6.44 0.26 4.0 8 6.47 0.16 2.5 
Organs Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
Kidney 8 0.60 0.051 8.5 8 0.57 0.050 8.7 8 0.57 0.046 8.0 8 0.58 0.034 5.8 8 0.58 0.025 4.3 
Spleen 8 0.24 0.018 7.2 8 0.23 0.028 12.4 8 0.24 0.022 9.0 8 0.22 0.022 10.0 8 0.25 0.018 7.4 
Liver 8 2.44 0.14 5.8 8 2.55 0.19 7.6 8 2.50 0.32 12.8 8 2.53 0.17 6.6 8 2.39 0.08 3.5 
AdrenGl 8 0.031 0.0033 10.5 8 0.028 0.0024 8.7 8 0.028 0.0018 6.2 8 0.028 0.0028 10.0 8 0.029 0.0017 5.8 
Heart 8 0.32 0.017 5.4 8 0.31 0.041 13.0 8 0.31 0.019 6.2 8 0.31 0.021 6.7 8 0.32 0.032 9.9 
Thymus 8 0.12 0.020 17.2 8 0.12 0.017 14.2 8 0.12 0.025 20.8 8 0.12 0.021 18.5 8 0.12 0.016 13.3 
Uterus 8 0.25 0.049 19.5 8 0.26 0.083 32.4 8 0.24 0.048 19.6 8 0.25 0.058 22.8 8 0.31 0.053 16.8 
Ovary 8 0.038 0.0026 6.9 8 0.034 0.0028 8.4 8 0.035 0.0057 16.1 8 0.036 0.0028 7.8 8 0.032 0.0012 3.7 
Brain 8 0.84 0.057 6.8 8 0.85 0.040 4.7 8 0.83 0.045 5.4 8 0.83 0.052 6.3 8 0.82 0.024 2.9 
Immunology Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
Granulocytes 5 76.8 3.18 4.1 5 71.0 5.87 8.3 5 77.7 3.24 4.2 5 73.5 3.14 4.3 5 73.1 3.65 5.0 
RespirBurst 5 56.3 13.2 23.5 5 52.4 1.8 3.4 5 54.5 6.1 11.2 5 52.3 11.7 22.3 5 57.9 7.8 13.5 
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Con 5 51683 19272 37.3 5 61830 17753 28.7 5 54694 25288 46.2 5 65130 25868 39.7 5 63123 20824 33.0 
PHA 5 29498 13084 44.4 5 36438 17117 47.0 5 27484 15738 57.3 5 34743 10510 30.3 5 36871 8194 22.2 
PWM 5 18769 15085 80.4 5 23672 6233 26.3 5 18101 9659 53.4 5 22491 10344 46.0 5 25289 15832 62.6 
Medium 5 1429 545 38.1 5 1685 219 13.0 5 1422 646 45.4 5 1788 533 29.8 5 1870 695 37.2 
IprConA 5 38.0 10.0 26.3 5 37.5 10.9 29.0 5 37.8 7.9 20.8 5 36.6 5.8 15.8 5 36.0 4.9 13.7 
IprPHA 5 21.4 5.57 26.0 5 21.8 9.32 42.8 5 19.9 5.56 28.0 5 21.7 7.81 36.0 5 21.7 6.15 28.4 
IprPWM 5 11.4 5.42 47.7 5 13.6 3.75 27.5 5 12.7 2.56 20.2 5 12.2 2.60 21.3 5 13.2 5.55 42.1 
Cytokines Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
IL2 3 3821 583 15.2 3 4491 285 6.3 4 3240 1267 39.1 3 3936 243 6.2 4 3434 1320 38.4 
IL4 3 14.2 2.0 14.3 3 12.1 2.1 17.6 4 9.5 4.8 50.0 3 25.9 14.3 55.2 4 11.1 7.0 62.9 
IL10 3 10919 11461 105.0 3 9553 9833 102.9 4 4401 2669 60.6 3 11809 8515 72.1 4 8175 11715 143.3 
IL17A 3 201 43.4 21.5 3 115 28.1 24.4 4 103 55.3 53.6 3 185 49.9 27.0 4 105 69.1 66.1 
TNFa 3 19.9 5.19 26.2 3 15.6 1.08 6.9 4 12.2 5.86 48.0 3 21.7 1.02 4.7 4 13.7 6.41 46.8 
IFNg 3 12364 4658 37.7 3 9788 2098 21.4 4 8656 5507 63.6 3 13476 1975 14.7 4 9123 6293 69.0 
CellPhenotype Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
sp3 5 37.1 2.17 5.8 5 41.8 3.75 9.0 5 38.6 4.84 12.5 5 39.7 5.88 14.8 5 41.1 3.56 8.7 
sp3_4 5 20.6 1.42 6.9 5 24.9 3.97 15.9 5 21.7 5.59 25.8 5 24.0 5.11 21.3 5 23.2 2.81 12.1 
sp3_8 5 16.1 0.91 5.6 5 15.7 1.57 10.0 5 15.5 0.74 4.8 5 15.2 1.68 11.1 5 17.2 1.99 11.6 
sp3_45 5 25.6 0.36 1.4 5 25.7 0.63 2.5 5 25.5 0.73 2.9 5 25.1 0.26 1.0 5 25.7 0.87 3.4 
sp3_161 5 11.1 0.61 5.5 5 10.9 0.31 2.8 5 11.0 0.57 5.2 5 10.9 0.11 1.0 5 11.3 1.08 9.6 
ln3 5 61.4 2.56 4.2 5 61.1 4.69 7.7 5 61.9 2.81 4.5 5 61.9 3.97 6.4 5 64.8 2.82 4.4 
ln3_4 5 44.8 2.48 5.5 5 45.5 4.26 9.4 5 45.1 3.99 8.9 5 46.1 3.95 8.6 5 47.0 2.77 5.9 
ln3_8 5 17.0 0.61 3.6 5 16.0 1.27 7.9 5 16.9 1.74 10.3 5 16.3 0.58 3.6 5 18.1 1.91 10.5 
ln3_45 5 20.4 6.90 33.8 5 25.6 9.26 36.1 5 21.7 7.71 35.4 5 22.0 8.27 37.5 5 18.4 5.49 29.9 
ty3 5 20.0 4.11 20.5 5 19.7 3.50 17.8 5 20.0 2.08 10.4 5 20.6 4.79 23.2 5 19.9 3.56 17.9 
ty3_4 5 15.2 3.75 24.6 5 15.3 3.03 19.8 5 15.8 1.87 11.9 5 15.4 3.79 24.6 5 14.8 2.47 16.7 
ty3_8 5 8.71 2.49 28.6 5 7.94 1.71 21.5 5 8.33 2.61 31.3 5 8.64 2.40 27.8 5 8.11 2.32 28.7 
Hormone Control NK11- NK33- NK11+ NK33+ 
Female N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV N Mean Sd CV 
betaEstr 8 7.74 4.51 58.3 8 4.98 3.45 69.4 8 4.63 1.35 29.2 8 5.04 2.08 41.1 8 4.64 1.29 27.8 
T3 8 0.76 0.16 21.4 8 0.77 0.12 15.2 8 0.69 0.08 11.9 8 0.73 0.13 18.1 8 0.63 0.12 18.8 
T4 8 34.2 7.9 23.2 8 31.0 8.5 27.4 8 34.0 11.4 33.4 8 37.8 9.0 24.0 8 25.4 8.5 33.4 
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4 Statistical analysis 
4.1 Equivalence testing using historical data 
4.1.1 Method 
Equivalence testing was introduced for GM safety assessment for compositional data in the EFSA 
guidance for risk assessment of food and feed from GM plants (EFSA 2011a). In the context of 90-day 
studies in rodents, EFSA (2014) recognized the potential advantages of equivalence testing and 
recommended further investigation. In response to this , an equivalence test was developed in the G-
TwYST project. This test compares the difference between a test (T) and a control (C) feed, obtained 
simultaneously in a current study, to the typical differences between reference (R) varieties obtained 
in one or more historical studies (van der Voet et al, 2017). The equivalence test is corrected for 
between-study differences, and the within-study variation between references R is used to set 
equivalence limits for the difference between T and C in the current study. The so-called Distribution 
Wise Equivalence (DWE) criterion is used in this test. An equivalence limit for the current study is set 
using the concept of desired power in a simplified situation, where there is no between-reference 
variation, where the historical and current studies have the same residual variance, and where the 
current study is assumed to have a sample size as approved by a regulator. The method is fully 
described in van der Voet et al (2017) .  
The equivalence test of van der Voet et al (2017) requires, employing the historic GRACE studies, 
calculation of the within-study between reference feeds sums of squares (𝑆𝑆𝑆𝑆𝑅𝑅), the residual sums of 
squares (𝑆𝑆𝑆𝑆𝐸𝐸) and their associated degrees of freedom 𝑑𝑑𝑓𝑓𝑅𝑅 and 𝑑𝑑𝑓𝑓𝐸𝐸. It also involves the effective unit 
replication 𝑛𝑛𝑊𝑊𝑒𝑒𝑒𝑒 which is necessary to estimate the between reference variance employing the mean 
squares for feeds and for residuals. The required values based on the five GRACE studies A-E are 
given in Appendix 9. 
The test also requires, for the current G-TwYST study, estimates of differences between the GMO 
feeds and the control feed, as well as the residual sums of squares and the associated degrees of 
freedom resulting from an analysis of variance. These are given in Appendix 10.  
The equivalence limit 𝜃𝜃0 for the DWE criterion is only based on the design values of the historical 
studies and on three regulatory values: the minimal regulatory sample size 𝑛𝑛0, a probability 𝛼𝛼 which 
defines a 100(1 − 𝛼𝛼)% confidence interval for the difference in the current study, and a probability 
𝛽𝛽 which defines the desired power 1 − 𝛽𝛽 for the equivalence test. We used values 𝑛𝑛0 = 8, 𝛼𝛼 = 0.05 
and 𝛽𝛽 = 0.05 resulting in a power of 0.95. Note that the regulatory sample size 𝑛𝑛0 = 8 equals the 
replication, i.e. the number of cages, for most variables in both the GRACE and the G-TwYST studies. 
Furthermore the equivalence limit 𝜃𝜃0 is calculated by simulating a large number of datasets in a 
simplified situation, where for each datasets an upper 100(1 − 𝛼𝛼)% percentile, 𝜃𝜃𝑢𝑢𝑢𝑢𝑢𝑢0 , for the DWE 
criterion is approximated by a large number of so-called GPQ samples. We simulated 40,000 datasets 
with 15,000 GPQ samples for each dataset. Note that 𝜃𝜃0 is calculated as the upper 100(1 − 𝛽𝛽)% 
percentile of the thus obtained 40.000 values of 𝜃𝜃𝑢𝑢𝑢𝑢𝑢𝑢0 . The DWE criterion for the current dataset was 
approximated by means of 100,000 GPQ samples. Note that the equivalence limit 𝜃𝜃0 is calculated 
assuming a regulatory sample size 𝑛𝑛0 = 8 which implies 14 degrees of freedom for residual in the 
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current study. The current G-TwYST study indeed has replication 8 but has 28 degrees of freedom for 
residual. 
The DWE equivalence test results in a DWE interval as a so-called equivalence limit scaled difference 
(ELSD), which can be used both for difference and for equivalence testing. The hypothesis of no 
difference is rejected in case the interval does not contain zero, while the non-equivalence 
hypothesis is rejected when the interval fully lies inside the interval (-1,1). For further interpretation, 
the confidence intervals are also presented at the original ratio scale, with inclusion of the estimated 
equivalence limits (red bars) and their uncertainty (blue bars). Note that the latter graphs cannot be 
used directly for performing the equivalence test. However, they show the effects and equivalence 
limits at a more familiar scale. 
4.1.2 Results 
Each GMO feed was tested for equivalence with respect to the control feed. The DWE intervals 
showing the main results of the equivalence tests for 42 variables (with two variables only for males, 
and two others only for females) are given in Figure 5 to Figure 8. For further interpretation the 95% 
confidence intervals for the ratios are given in Table 8 and Table 9, and these intervals and limits at 
the ratio scale are given in Figure 9 to Figure 16. 
The DWE equivalence test depends, among other things, on the ratio of the residual variance of the 
current study and the residual variance of the historical studies. In case this ratio is small the 
corresponding DWE interval will generally be short. The ratio of the residual variances is given in 
Figure 17. Small ratios are observed for e.g. Ca, Cl, and Na for both sexes. Large ratios are observed 
for Lymphocytes in both sexes, and HCT, RBC, Eosinophils and some organ weights in females. 
Among 320 equivalence tests, there were 19 failures (6%) to prove equivalence (i.e. reject the 
hypothesis of non-equivalence), which is close to the 5% level of the test. In all these 19 cases the 
median estimate was within the equivalence limits, therefore equivalence is still more likely than lack 
of equivalence according to the terminology of EFSA (2011a). These 19 cases are observed for 
Lymphocytes in males (4x), while the remaining 15 cases are observed in females for Lymphocytes 
(4x), HCT (4x), Eosinophils (2x), kidney weight (2x), RBC (1x), uterus weight (1x) and growthRate (1x). 
From Figure 17 it can be seen that these are all cases where the G-TwYST study B was less precise 
than the historical studies on average (residual variance 1.5 to 3 times higher than in the historical 
datasets). 
Although not the primary result of the equivalence analysis, it can also be observed from the graphs 
and tables that, for those variables for which the equivalence test is performed, the number of 
significant differences, employing t-tests, equals 25 (8% of 320 difference tests), which is again close 
to the 5% level of the test. Only in three of these cases (Lymphocytes males NK33- and growthRate 
females NK11- and NK33+) there was both a significant difference and a failure to show equivalence. 
For all 632 difference tests, i.e. including those for which the equivalence test was not performed, 55 
t-tests were significant which is 9% of the tests.  
.  
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Figure 5 Equivalence testing of NK11- and NK33- versus the control feed for males. For estimates 
(square symbols) on the left of zero the GM feed has a smaller mean than the control 
feed. See Table 8, Figure 9 and Figure 10 for further interpretation. 
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Figure 6 Equivalence testing of NK11+ and NK33+ versus the control feed for males. For estimates 
(square symbols) on the left of zero the GM feed has a smaller mean than the control 
feed. See Table 8, Figure 11 and Figure 12 for further interpretation. 
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Figure 7 Equivalence testing of NK11- and NK33- versus the control feed for females. For 
estimates (square symbols) on the left of zero the GM feed has a smaller mean than the 
control feed. See Table 9, Figure 13 and Figure 14 for further interpretation. 
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Figure 8 Equivalence testing of NK11+ and NK33+ versus the control feed for females. For 
estimates (square symbols) on the left of zero the GM feed has a smaller mean than the 
control feed. See Table 9, Figure 15 and Figure 16 for further interpretation. 
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Table 8 95% Confidence interval plus estimate for the ratio Δ of the GMO feeds versus the Control feed for males. Intervals are based on an ANOVA 
with 5 feeding groups. Ratios with corresponding Intervals that do not encompass the value 1 are coloured red; this is equivalent to a 
significant difference according to a t-test with significance level 5%. 
Weights NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
BodyWeight 1.001 1.049 1.101 0.974 1.021 1.071 0.944 0.991 1.039 0.990 1.038 1.089 
growthRate 0.968 0.991 1.014 0.967 0.990 1.013 0.978 1.001 1.024 0.976 0.999 1.022 
FeedMean 0.968 1.017 1.069 0.970 1.019 1.071 0.899 0.945 0.993 0.948 0.996 1.047 
Haematology NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
WBC 0.817 0.976 1.167 0.875 1.046 1.250 0.909 1.086 1.299 0.894 1.069 1.278 
RBC 0.951 0.994 1.040 0.954 0.997 1.043 0.940 0.983 1.029 0.961 1.005 1.052 
HGB 0.982 1.006 1.030 0.982 1.006 1.030 0.957 0.980 1.003 0.989 1.013 1.038 
HCT 0.974 1.010 1.046 0.981 1.016 1.053 0.965 1.000 1.037 0.983 1.019 1.056 
MCV 0.994 1.015 1.037 0.998 1.019 1.041 0.996 1.017 1.039 0.993 1.014 1.035 
MCH 0.967 0.995 1.024 0.980 1.008 1.038 0.968 0.996 1.025 0.979 1.008 1.037 
MCHC 0.961 0.980 0.999 0.971 0.990 1.009 0.961 0.980 0.999 0.975 0.994 1.014 
PLT 0.787 0.919 1.072 0.870 1.016 1.185 0.866 1.010 1.179 0.840 0.980 1.143 
LYMR 0.926 0.994 1.067 0.899 0.965 1.036 0.920 0.988 1.060 0.938 1.006 1.080 
LYMA 0.804 0.969 1.168 0.837 1.009 1.217 0.889 1.072 1.292 0.892 1.075 1.296 
diffWBC NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
Lymphocytes 0.885 0.954 1.029 0.850 0.917 0.988 0.908 0.979 1.055 0.918 0.990 1.068 
Neutrophils 0.950 1.122 1.327 1.006 1.189 1.406 0.882 1.043 1.233 0.868 1.026 1.213 
Monocytes 0.832 1.133 1.544 0.827 1.127 1.536 0.777 1.059 1.443 0.651 0.888 1.209 
Eosinophils 0.601 0.925 1.421 0.737 1.132 1.741 0.774 1.190 1.830 0.780 1.198 1.842 
ClinChem NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
ALP 0.914 1.020 1.139 0.914 1.020 1.140 0.891 0.995 1.112 1.026 1.146 1.279 
ALT 0.916 1.018 1.131 0.874 0.972 1.080 0.797 0.886 0.984 0.886 0.985 1.095 
AST 0.837 0.963 1.108 0.820 0.943 1.085 0.775 0.892 1.027 0.810 0.932 1.073 
BIL 0.880 0.991 1.117 0.866 0.975 1.099 0.892 1.005 1.132 0.813 0.916 1.032 
ALB 0.978 1.006 1.035 0.986 1.014 1.043 1.010 1.039 1.068 0.972 0.999 1.028 
TP 0.992 1.011 1.030 0.991 1.010 1.029 1.009 1.029 1.048 0.985 1.004 1.023 
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Glu 0.902 1.004 1.118 0.845 0.941 1.048 0.878 0.977 1.088 0.928 1.033 1.150 
CHOL 0.883 0.974 1.076 0.899 0.992 1.095 0.857 0.946 1.044 0.908 1.003 1.107 
TAG 0.908 1.089 1.305 0.858 1.029 1.234 0.819 0.982 1.178 0.866 1.038 1.245 
Crea 0.954 1.032 1.117 0.939 1.016 1.099 1.004 1.087 1.176 0.964 1.044 1.129 
Urea 0.872 0.953 1.041 0.891 0.973 1.062 0.871 0.952 1.039 0.882 0.964 1.052 
cHGB 0.706 0.954 1.289 0.702 0.949 1.282 0.628 0.849 1.148 0.588 0.795 1.075 
Ca 0.986 0.999 1.013 0.988 1.002 1.016 0.991 1.005 1.019 0.982 0.996 1.010 
Cl 0.988 0.997 1.006 0.988 0.997 1.006 0.991 1.001 1.010 0.991 1.000 1.010 
K 0.970 1.016 1.064 1.004 1.052 1.102 1.000 1.047 1.096 0.977 1.023 1.072 
Na 0.993 1.001 1.009 0.996 1.004 1.012 0.997 1.006 1.014 0.995 1.003 1.011 
P 0.942 1.032 1.131 0.970 1.063 1.165 0.935 1.025 1.124 0.893 0.979 1.073 
Urine NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
uVol 0.704 0.954 1.292 0.780 1.056 1.430 0.765 1.035 1.402 0.725 0.982 1.330 
uVolW 0.669 0.908 1.232 0.764 1.036 1.406 0.769 1.043 1.414 0.697 0.945 1.282 
uLeu 0.522 0.934 1.669 0.559 1.000 1.788 0.522 0.934 1.669 0.559 1.000 1.788 
uOsmoll 0.763 0.975 1.246 0.709 0.906 1.158 0.726 0.928 1.186 0.788 1.008 1.288 
uKeton 0.646 1.867 5.394 0.437 1.261 3.643 0.365 1.055 3.049 0.231 0.667 1.928 
upH 0.688 0.882 1.132 0.607 0.779 0.999 0.647 0.829 1.063 0.536 0.687 0.881 
Organs NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
Kidney 0.935 1.007 1.085 0.958 1.032 1.112 0.975 1.051 1.132 0.919 0.990 1.067 
Spleen 0.956 1.040 1.132 0.902 0.981 1.068 0.968 1.054 1.146 0.928 1.009 1.098 
Liver 0.972 1.013 1.056 0.995 1.037 1.081 0.997 1.039 1.084 0.964 1.005 1.048 
AdrenGl 0.842 0.934 1.037 0.848 0.941 1.044 0.826 0.916 1.016 0.849 0.942 1.045 
Heart 0.987 1.041 1.098 0.973 1.026 1.082 0.973 1.026 1.082 0.942 0.994 1.048 
Thymus 0.944 1.065 1.201 0.964 1.088 1.227 1.026 1.157 1.305 0.938 1.058 1.193 
Testis 0.931 0.996 1.065 0.952 1.018 1.089 0.969 1.036 1.108 0.935 1.000 1.069 
Epididymis 0.914 0.989 1.069 0.967 1.046 1.131 0.954 1.032 1.116 0.943 1.020 1.103 
Brain 0.928 0.977 1.029 0.980 1.032 1.088 0.988 1.041 1.096 0.950 1.000 1.054 
Immunology NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
Granulocytes 1.001 1.062 1.127 0.943 1.000 1.061 0.939 0.996 1.057 0.944 1.002 1.063 
RespirBurst 0.900 1.037 1.194 0.809 0.932 1.074 0.805 0.927 1.068 0.858 0.988 1.138 
Con 0.645 1.038 1.671 0.634 1.020 1.643 0.564 0.908 1.462 0.758 1.221 1.966 
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PHA 0.762 1.131 1.678 0.758 1.124 1.668 0.624 0.927 1.375 0.799 1.186 1.759 
PWM 0.829 1.445 2.518 0.589 1.026 1.788 0.584 1.017 1.773 1.053 1.835 3.197 
Medium 0.612 0.972 1.542 0.550 0.872 1.384 0.505 0.801 1.272 0.795 1.261 2.001 
IprConA 0.667 1.069 1.712 0.750 1.201 1.925 0.707 1.132 1.813 0.602 0.965 1.546 
IprPHA 0.792 1.173 1.738 0.879 1.302 1.929 0.792 1.174 1.739 0.643 0.953 1.412 
IprPWM 1.098 1.487 2.014 0.878 1.189 1.611 0.945 1.280 1.734 1.080 1.463 1.981 
Cytokines NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
IL2 1.124 1.374 1.678 0.937 1.145 1.399 0.912 1.115 1.362 1.146 1.400 1.711 
IL4 0.538 0.794 1.171 0.418 0.617 0.910 0.417 0.616 0.908 0.528 0.778 1.148 
IL10 0.457 1.216 3.238 0.236 0.629 1.675 0.201 0.535 1.424 0.728 1.939 5.161 
IL17A 0.512 1.122 2.460 0.418 0.916 2.009 0.295 0.646 1.415 0.646 1.416 3.104 
TNFa 1.140 1.602 2.251 0.789 1.109 1.559 0.815 1.146 1.611 1.174 1.650 2.319 
IFNg 1.216 1.702 2.383 0.765 1.071 1.500 0.774 1.084 1.518 1.022 1.432 2.005 
CellPhenotype NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
sp3 0.977 1.150 1.353 0.904 1.064 1.252 1.035 1.218 1.434 1.010 1.188 1.399 
sp3_4 0.942 1.120 1.332 0.955 1.136 1.351 1.010 1.202 1.429 1.024 1.217 1.448 
sp3_8 0.972 1.167 1.400 0.794 0.952 1.143 1.034 1.241 1.489 0.942 1.131 1.357 
sp3_45 0.975 1.027 1.082 0.941 0.996 1.053 0.936 0.986 1.039 0.962 1.014 1.068 
sp3_161 0.887 0.968 1.056 0.925 1.016 1.116 0.912 0.995 1.086 0.844 0.921 1.006 
ln3 0.848 1.020 1.227 0.765 0.920 1.106 0.742 0.893 1.074 0.775 0.933 1.122 
ln3_4 0.773 0.959 1.189 0.730 0.906 1.123 0.677 0.840 1.042 0.727 0.902 1.119 
ln3_8 0.984 1.157 1.361 0.832 0.979 1.151 0.894 1.051 1.236 0.869 1.022 1.202 
ln3_45 0.673 0.819 0.997 0.688 0.837 1.018 0.779 0.948 1.154 0.723 0.879 1.070 
ty3 0.861 1.024 1.217 0.903 1.073 1.276 0.941 1.119 1.329 0.947 1.126 1.338 
ty3_4 0.865 1.018 1.199 0.919 1.082 1.274 0.955 1.125 1.325 0.968 1.140 1.343 
ty3_8 0.875 1.050 1.261 0.878 1.054 1.265 0.881 1.058 1.270 0.953 1.144 1.373 
Hormone NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Males Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
Testosteron 0.561 0.900 1.443 0.420 0.673 1.080 0.608 0.975 1.564 0.499 0.800 1.283 
T3 0.971 1.081 1.203 0.890 0.990 1.103 0.889 0.989 1.101 0.965 1.074 1.196 
T4 0.891 0.977 1.072 0.806 0.884 0.969 0.912 1.000 1.097 0.883 0.969 1.063 
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Table 9 95% Confidence interval plus estimate for the ratio Δ of the GMO feeds versus the Control feed for females. Intervals are based on an ANOVA 
with 5 feeding groups. Ratios with corresponding Intervals that do not encompass the value 1 are coloured red; this is equivalent to a 
significant difference according to a t-test with significance level 5%. 
Weights NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
BodyWeight 0.948 0.989 1.033 0.974 1.017 1.062 0.966 1.009 1.053 0.989 1.033 1.078 
growthRate 1.001 1.039 1.079 0.997 1.035 1.074 0.997 1.035 1.075 1.021 1.060 1.100 
FeedMean 0.851 0.913 0.981 0.924 0.992 1.065 0.907 0.974 1.046 0.933 1.001 1.075 
Haematology NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
WBC 0.816 0.998 1.219 0.920 1.124 1.373 0.740 0.904 1.105 0.813 0.993 1.214 
RBC 0.941 0.996 1.054 0.965 1.021 1.081 0.954 1.010 1.069 0.934 0.988 1.046 
HGB 0.950 0.986 1.024 0.990 1.029 1.068 0.971 1.008 1.047 0.952 0.989 1.027 
HCT 0.941 0.989 1.039 0.978 1.028 1.081 0.962 1.011 1.063 0.955 1.004 1.055 
MCV 0.967 0.992 1.019 0.981 1.007 1.033 0.975 1.001 1.027 0.990 1.016 1.042 
MCH 0.958 0.990 1.024 0.975 1.008 1.042 0.966 0.999 1.032 0.968 1.000 1.034 
MCHC 0.977 0.997 1.018 0.980 1.000 1.021 0.977 0.997 1.018 0.965 0.984 1.004 
PLT 0.800 0.915 1.045 0.877 1.002 1.145 0.793 0.906 1.035 0.888 1.014 1.159 
LYMR 0.938 0.998 1.063 0.971 1.033 1.100 0.958 1.019 1.085 0.965 1.027 1.093 
LYMA 0.797 0.993 1.238 0.931 1.160 1.446 0.738 0.920 1.147 0.814 1.014 1.264 
diffWBC NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
Lymphocytes 0.925 1.004 1.089 0.941 1.021 1.107 0.959 1.041 1.129 0.949 1.030 1.117 
Neutrophils 0.817 1.005 1.236 0.782 0.962 1.183 0.758 0.932 1.146 0.750 0.923 1.135 
Monocytes 0.514 0.754 1.105 0.580 0.851 1.247 0.556 0.815 1.194 0.583 0.855 1.253 
Eosinophils 0.445 0.962 2.081 0.555 1.202 2.599 0.348 0.753 1.629 0.711 1.538 3.327 
ClinChem NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
ALP 0.872 1.015 1.182 0.983 1.145 1.333 0.873 1.016 1.183 0.859 1.001 1.165 
ALT 0.736 0.897 1.095 0.886 1.081 1.318 0.762 0.930 1.134 0.740 0.903 1.101 
AST 0.844 0.990 1.161 0.894 1.049 1.230 0.834 0.978 1.147 0.891 1.045 1.226 
BIL 0.826 0.938 1.066 0.942 1.071 1.216 0.910 1.033 1.174 0.961 1.092 1.241 
ALB 0.921 0.978 1.038 0.991 1.052 1.116 0.980 1.040 1.104 0.976 1.036 1.100 
TP 0.942 0.979 1.018 0.995 1.035 1.076 0.993 1.032 1.074 0.988 1.027 1.068 
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Glu 0.833 0.959 1.104 0.726 0.836 0.963 0.830 0.955 1.100 0.924 1.064 1.225 
CHOL 0.942 1.070 1.214 0.931 1.056 1.199 0.931 1.056 1.198 0.917 1.040 1.181 
TAG 0.927 1.133 1.385 1.044 1.276 1.560 0.965 1.179 1.441 0.905 1.106 1.352 
Crea 0.927 1.026 1.136 0.943 1.044 1.156 0.891 0.986 1.092 0.919 1.017 1.126 
Urea 0.893 1.007 1.135 0.802 0.904 1.019 0.794 0.896 1.010 0.842 0.949 1.070 
cHGB 0.691 0.977 1.382 0.817 1.155 1.634 0.806 1.140 1.612 0.859 1.215 1.719 
Ca 0.975 0.993 1.011 0.989 1.007 1.026 0.991 1.010 1.028 0.991 1.009 1.028 
Cl 0.987 0.999 1.011 0.973 0.985 0.998 0.982 0.994 1.007 0.987 0.999 1.012 
K 0.946 1.002 1.061 0.958 1.014 1.074 0.962 1.019 1.080 0.995 1.054 1.116 
Na 0.984 0.994 1.004 0.987 0.997 1.007 0.990 1.000 1.010 0.988 0.998 1.008 
P 0.844 0.959 1.090 0.924 1.050 1.193 0.835 0.949 1.078 0.845 0.960 1.091 
Urine NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
uVol 0.709 0.958 1.295 0.685 0.926 1.252 0.681 0.920 1.244 0.593 0.801 1.082 
uVolW 0.710 0.970 1.324 0.667 0.911 1.244 0.667 0.911 1.244 0.568 0.775 1.058 
uLeu 0.550 0.872 1.382 0.513 0.814 1.290 0.723 1.147 1.819 0.550 0.872 1.382 
uOsmoll 0.754 0.993 1.309 0.782 1.030 1.357 0.758 0.999 1.316 0.803 1.059 1.395 
uKeton 0.572 0.760 1.010 0.692 0.919 1.221 0.572 0.760 1.010 0.534 0.709 0.943 
upH 0.650 0.829 1.057 0.692 0.882 1.126 0.650 0.829 1.057 0.671 0.855 1.091 
Organs NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
Kidney 0.878 0.951 1.030 0.879 0.952 1.031 0.893 0.967 1.047 0.897 0.971 1.052 
Spleen 0.837 0.917 1.005 0.912 0.999 1.095 0.806 0.884 0.969 0.909 0.997 1.092 
Liver 0.967 1.039 1.117 0.943 1.013 1.089 0.960 1.032 1.109 0.910 0.977 1.050 
AdrenGl 0.825 0.899 0.981 0.835 0.911 0.993 0.836 0.912 0.995 0.860 0.938 1.023 
Heart 0.894 0.966 1.044 0.882 0.953 1.030 0.891 0.963 1.040 0.925 1.000 1.080 
Thymus 0.874 1.034 1.222 0.879 1.039 1.229 0.828 0.979 1.158 0.861 1.018 1.204 
Uterus 0.788 0.998 1.264 0.760 0.963 1.219 0.797 1.009 1.278 0.943 1.194 1.512 
Ovary 0.795 0.879 0.973 0.838 0.927 1.025 0.856 0.947 1.048 0.772 0.854 0.945 
Brain 0.974 1.018 1.063 0.951 0.993 1.037 0.947 0.989 1.033 0.934 0.976 1.019 
Immunology NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
Granulocytes 0.848 0.914 0.985 0.939 1.012 1.091 0.888 0.957 1.031 0.879 0.947 1.021 
RespirBurst 0.777 0.950 1.160 0.804 0.982 1.200 0.769 0.940 1.148 0.857 1.047 1.279 
Con 0.690 1.289 2.407 0.496 0.926 1.729 0.702 1.312 2.450 0.718 1.340 2.503 
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PHA 0.657 1.220 2.265 0.457 0.848 1.574 0.695 1.290 2.394 0.753 1.399 2.597 
PWM 0.880 1.644 3.075 0.618 1.156 2.161 0.829 1.550 2.899 0.892 1.668 3.118 
Medium 0.836 1.287 1.983 0.612 0.943 1.453 0.861 1.326 2.042 0.905 1.394 2.147 
IprConA 0.719 1.019 1.444 0.685 0.970 1.375 0.718 1.018 1.442 0.699 0.990 1.403 
IprPHA 0.561 0.938 1.569 0.543 0.908 1.519 0.580 0.970 1.622 0.594 0.993 1.662 
IprPWM 0.839 1.252 1.870 0.820 1.224 1.828 0.756 1.128 1.684 0.790 1.180 1.762 
Cytokines NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
IL2 0.899 1.166 1.513 0.746 0.960 1.235 0.799 1.036 1.344 0.791 1.018 1.310 
IL4 0.379 0.872 2.009 0.414 0.928 2.081 0.631 1.452 3.344 0.367 0.824 1.848 
IL10 0.173 0.819 3.885 0.178 0.802 3.620 0.245 1.162 5.507 0.231 1.042 4.700 
IL17A 0.279 0.466 0.778 0.376 0.619 1.017 0.546 0.912 1.524 0.357 0.587 0.966 
TNFa 0.530 0.773 1.127 0.505 0.727 1.048 0.778 1.134 1.653 0.584 0.841 1.212 
IFNg 0.442 0.896 1.818 0.459 0.911 1.807 0.601 1.220 2.476 0.442 0.878 1.741 
CellPhenotype NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
sp3 0.977 1.123 1.291 0.900 1.034 1.189 0.921 1.058 1.216 0.956 1.099 1.263 
sp3_4 0.968 1.195 1.476 0.835 1.031 1.273 0.919 1.135 1.402 0.902 1.113 1.375 
sp3_8 0.867 0.979 1.105 0.853 0.964 1.088 0.836 0.944 1.066 0.947 1.070 1.208 
sp3_45 0.972 1.005 1.039 0.966 0.999 1.032 0.949 0.981 1.014 0.972 1.004 1.039 
sp3_161 0.909 0.979 1.055 0.916 0.987 1.063 0.906 0.977 1.052 0.939 1.012 1.091 
ln3 0.917 0.991 1.071 0.933 1.009 1.090 0.934 1.009 1.090 0.976 1.055 1.140 
ln3_4 0.912 1.011 1.121 0.904 1.002 1.112 0.925 1.026 1.138 0.943 1.046 1.160 
ln3_8 0.862 0.944 1.034 0.909 0.996 1.090 0.879 0.962 1.054 0.971 1.063 1.164 
ln3_45 0.915 1.245 1.694 0.783 1.066 1.451 0.794 1.080 1.469 0.668 0.909 1.237 
ty3 0.863 0.984 1.122 0.881 1.005 1.146 0.897 1.023 1.166 0.873 0.996 1.135 
ty3_4 0.872 1.010 1.171 0.906 1.051 1.218 0.869 1.007 1.168 0.848 0.983 1.140 
ty3_8 0.822 0.928 1.049 0.840 0.949 1.072 0.882 0.997 1.126 0.824 0.930 1.051 
Hormone NK11- vs Control NK33- vs Control NK11+ vs Control NK33+ vs Control 
Females Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper Lower Ratio Upper 
betaEstr 0.416 0.617 0.914 0.446 0.662 0.981 0.443 0.657 0.974 0.426 0.632 0.937 
T3 0.863 1.033 1.237 0.778 0.932 1.116 0.820 0.982 1.175 0.704 0.843 1.009 
T4 0.594 0.856 1.235 0.642 0.926 1.335 0.793 1.144 1.649 0.467 0.673 0.971 
 Figure 9 Confidence intervals for the ratio of NK11- and the Control feed for males with added 
intervals for the equivalence limits (blue and red bars, see text). 
G-TwYST Study B  Statistical report 
33 
 
 
Figure 10 Confidence intervals for the ratio of NK33- and the Control feed for males with added 
intervals for the equivalence limits (blue and red bars, see text). 
G-TwYST Study B  Statistical report 
34 
 
 
Figure 11 Confidence intervals for the ratio of NK11+ and the Control feed for males with added 
intervals for the equivalence limits (blue and red bars, see text). 
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Figure 12 Confidence intervals for the ratio of NK33+ and the Control feed for males with added 
intervals for the equivalence limits (blue and red bars, see text). 
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Figure 13 Confidence intervals for the ratio of NK11- and the Control feed for females with added 
intervals for the equivalence limits (blue and red bars, see text). 
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Figure 14 Confidence intervals for the ratio of NK33- and the Control feed for females with added 
intervals for the equivalence limits (blue and red bars, see text). 
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Figure 15 Confidence intervals for the ratio of NK11+ and the Control feed for females with added 
intervals for the equivalence limits (blue and red bars, see text). 
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Figure 16 Confidence intervals for the ratio of NK33+ and the Control feed for females with added 
intervals for the equivalence limits (blue and red bars, see text). 
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Figure 17 Residual variance (sig2F or 𝝈𝝈𝑭𝑭𝟐𝟐) in the current G-TwYST B study as a percentage of the 
residual variance (sig2E or 𝝈𝝈𝑬𝑬𝟐𝟐) in the historical GRACE studies for males (top panel) and 
females (bottom panel). 
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4.2 Equivalence testing using target effect sizes 
4.2.1 Method 
For a limited number of variables Hong et al (2017) use what they call targeted effect sizes for the 
purpose of statistical power analysis for a rat sub-chronic feeding study. Although they warn that 
these effect sizes should not be considered synonymous with biologically or toxicologically relevant 
effects, these targeted effect sizes were used for equivalence testing. The targeted effect sizes for 
nine variables that are also relevant in G-TwYST are given in Table 10 along with the implied limits on 
the log-ratio scale which are used in the equivalence test. Note the asymmetry in these limits: for a 
targeted effect size of +/- 30%, +30% corresponds to a factor 1.3 which is 0.262 on the log scale, 
while -30% corresponds to a factor 0.7 which equals -0.357 on the log scale. 
Table 10 Targeted effect sizes from Table 1 in Hong et al (2017) along with their implied lower 
and upper limits on the ratio scale and on the log-ratio scale. 
Name in Hong et al (2017) G-TwYST 
Name 
Targeted 
effect 
size 
Ratio scale Log-ratio scale 
Lower Upper Lower Upper 
Body weight; final non-fasted BodyWeight -  10% 0.90 - -0.105 - 
Leukocyte (WBC) count WBC +/-  30% 0.70 1.30 -0.357 0.262 
Lymphocyte (ALYM) count LYMA +/-  30% 0.70 1.30 -0.357 0.262 
Alkaline phosphatase (ALKP) ALP +  100% - 2.00 - 0.693 
Creatinine (CREA) Krea +  50% - 1.50 - 0.405 
Blood urea nitrogen (BUN) Urea +  50% - 1.50 - 0.405 
Cholesterol (CHOL)  CHOL +  200% - 3.00 - 1.099 
Kidney, % body weight Kidney +  25% - 1.25 - 0.223 
Liver, % body weight Liver +  25% - 1.25 - 0.223 
 
Denoting the limits on the log-ratio scale as 𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 and 𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢, the two-sided non-equivalence null 
hypothesis reads, with Δ the ratio of the mean of a GMO feed and the mean of the control feed: 
 𝐻𝐻0: log(𝛥𝛥) <  𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 or log(𝛥𝛥) >  𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢  
 𝐻𝐻1:  𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 ≤  log(𝛥𝛥) ≤  𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢 
This was tested by means of the TOST approach of Schuirmann (1987) at the 5% level which is 
equivalent to checking whether the 10% confidence interval for log(𝛥𝛥) lies completely within the 
interval �𝛿𝛿𝑙𝑙𝑙𝑙𝑙𝑙 ,𝛿𝛿𝑢𝑢𝑢𝑢𝑢𝑢� composed of the equivalence limits. For one-sided tests the same confidence 
interval can be used where only one of the confidence bounds is relevant.  
4.2.2 Results 
The confidence intervals for the 9 variables in Table 10, as well as the equivalence limits are given in 
Figure 18 for males and in Figure 19 for females. Only for WBC and LYMA for GMO feed NK33- 
administered to females the null hypothesis of non-equivalence is not rejected. In all other cases (70 
out of 72, or 97%) non-equivalence was rejected, and thus equivalence accepted, with generally 
small p-values (Table 11). For WBC and LYMA in Females NK33- equivalence was still more likely than 
not according to the terminology of EFSA (2011a). 
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Figure 18 90% confidence intervals for the ratio of the mean of the GMO feed and the control feed 
for selected variables for males along with equivalence intervals defined by targeted 
effect sizes of Hong et al (2017). 
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Figure 19 90% confidence intervals for the ratio of the mean of the GMO feed and the control feed 
for selected variables for females along with equivalence intervals defined by targeted 
effect sizes of Hong et al (2017). 
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Table 11 P-values of equivalence tests for the ratio of the mean of the GMO feed versus the mean 
of the control feed using targeted effect sizes of Hong et al (2017), see Table 10, as 
equivalence limits. P-values smaller than 0.01/0.05 have a gold/yellow background. 
Variable 
Males Females 
NK11- NK33- NK11+ NK33+ NK11- NK33- NK11+ NK33+ 
BodyWeight 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
WBC 0.001 0.009 0.024 0.016 0.006 0.074 0.007 0.005 
LYMA 0.002 0.005 0.022 0.023 0.009 0.149 0.008 0.014 
ALP 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Krea 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Urea 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
CHOL 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Kidney 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
Liver 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
 
4.3 Classical statistical analysis 
4.3.1 Method 
G-TwYST study B is based on OECD guidance 408 on repeated dose 90-day oral toxicity studies in 
rodents (OECD 1998), EFSA guidance complementing the OECD guidance for whole food/feed studies 
(EFSA 2011b), and additional EFSA clarifications (EFSA 2013, 2014). OECD guidance 408 (OECD 1998) 
requires numerical results to be evaluated by an appropriate and acceptable statistical method, but 
gives no further guidance on statistical analysis. More detailed guidance, although strictly meant for 
chronic and carcinogenicity studies, is provided in chapter 4 of OECD guidance document 116 (OECD 
2012), which describes a flowchart for statistical analysis methods (reproduced in Figure 20).  
 
Figure 20 Classical approach to statistical analysis of data in long-term toxicity studies (copied 
from OECD 2012). 
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EFSA (2011b) gives further guidance, such as considering cage as the experimental unit, and including 
block in the model for data from a randomised block design (as is the case for the G-TwYST study). 
In the current section we apply classical statistical methods for continuous data in line with these 
OECD and EFSA approaches, and very similar to the approaches followed in the GRACE project 
(Schmidt and Schmidtke 2014, Schmidt et al 2015ab). 
The following variables were not statistically analysed: 
• The observed weights in each week. The weights are summarized by means of the growth 
curve resulting in the growthRate variable and the final BodyWeight variable (section 3.1); 
• The observed feed intake in each week. These are summarized in the FeedMean variable 
which is the mean feed intake over the thirteen weeks; 
• Basophils: the observed number of basophils white blood cells is zero for all rats; 
• uColour: the colour of the urine was yellow (score 2) for all rats except for female rats 179 
and 180 which had light yellow urine (score 1). These two rats are both housed in cage 83 
and received the Control feed;  
• uBil: all measurements of bilirubin in urine are equal to zero; 
• uNit: all measurements of nitrites in urine equal zero except for the five male rats 16 (NK11-), 
48 (NK33-), 63 (NK11+), 64 (NK11+) and 79 (Control) which have the value one; 
• uProtein: all measurements of total protein in urine are equal to zero; 
• uGlu: all measurements of glucose in urine are equal to one; 
• uHemogl: all measurements of haemoglobin in urine are equal to zero, except for male rat 47 
(NK33-) which has a value 25 and for female rat 147 (NK33-) which has a value 1; 
• uUrobili: all measurements of urobilinogen in urine are equal to one; 
• IL1a: cytokine Interleukin 1 alpha equals 11.2 for most rats except male rats 73 (26.43, 
Control) and 76 (13.94, Control), and female rat 154 (14.1, NK11+); 
• IL1b: cytokine Interleukin 1 beta equals 15.9 except for male rat 37 (159.3, Control) which is 
most probably a typo; 
• IL5: cytokine Interleukin 5 equals 2.4 except for male rats 73 (5.2, Control) and 74 (3.3, 
Control), and female rats 105 (3.03, NK11-), 119 (2.55, NK33+) and 165 (3.42, Control); 
• IL6: cytokine Interleukin 6 equals 4.9 except for male rat 73 (7.34, Control); 
• IL12p70: cytokine Interleukin 12p70 equals 9.8 for 55 rats except for the 11 male rats 5 
(16.49, NK11-), 8 (14.27, NK11-), 10 (19.04, NK11-), 12 (12.89, NK11-), 13 (12.35, NK11-), 28 
(10.20, NK33+), 70 (39.21, Control), 71 (39.21, Control), 73 (44.60, Control), 74 (20.71, 
Control), 75 (16.83, Control) and 78 (18.60, Control), and the 14 female rats 101 (31.35, 
NK11-), 105 (17.89, NK11-), 118 (14.72, NK33+), 119 (16.83, NK33+), 149 (12.95, NK11+), 150 
(40.35, NK11+), 151 (61.66, NK11+), 152 (53.68, NK11+), 153 (42.68, NK11+), 154 (25.51, 
NK11+), 165 (50.13, Control), 166 (22.17, Control), 167 (20.70, Control) and 168 (30.39, 
Control); 
• IL13: cytokine Interleukin 13 equals 4.9 for 66 rats except for the 11 male rats 7 (5.58, NK11-
), 8 (7.41, NK11-), 12 (6.81, NK11-), 13 (6.26, NK11-), 22 (14.62, NK33+), 27 (10.37, NK33+), 53 
(7.07, NK11+), 69 (7.74, Control), 70 (6.37, Control), 71 (9.82, Control) and 73 (12.43, 
Control), and the 4 female rats 119 (5.05, NK33+), 150 (5.85, NK11+), 153 (7.07, NK11+) and 
165 (13.21, Control); 
• GCSF: cytokine granulocyte colony-stimulating factor equals 3.7 for all rats; 
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• GMCSF: cytokine granulocyte-macrophage colony-stimulating factor equals 9.8 for most rats 
except for the 7 male rats 7 (14.48, NK11-), 8 (18.05, NK11-), 14 (13.07, NK11-), 22 (14.08, 
NK33+), 70 (12.87, Control), 71 (12.55, Control) and 73 (19.18, Control), and the 3 female rats 
151 (13.30, NK11+), 154 (29.40, NK11+) and 165 (11.30, Control); 
A classical analysis of variance was performed on the cage means after log transforming the data. 
This was done in the statistical program R. The R-script which analyses a single response variable is 
given in Appendix 12; Appendix 13 contains an example dataset for the R-script. The classical analysis 
involves: 
• Analysis of variance according to the randomized block design employing the model “Block + 
Treatment” where Treatment defines the five feeding groups. The model was fitted by means of 
linear regression, using the lm() function in R, because this takes proper account of any missing 
values. The usual summary statistics are saved as well as estimates for the difference between 
GMO feeds and the control and corresponding standard errors, t-values and p-values. These are 
all calculated using the pooled ANOVA residual standard error which generally has 28 degrees of 
freedom. 
• The variables in the eCycle group are analysed separately. 
• The ANOVA p-values do not take account of multiple comparisons between the feeds. Therefore 
Dunnett’s test was performed, which also compares the GMO feeds with the control feed, 
taking account of the number of comparisons made. Dunnett’s test is performed by means of 
the glht() function in the multcomp R-package. 
• The residuals of the analysis of variance are checked for normality using the Kolmogorov-
Smirnov test as well as the Shapiro-Wilk test for normality. These tests are only approximate 
since the residuals are not independent. The p-value of the Kolmogorov-Smirnov test is not 
reported since it is almost always larger that the p-value of the Shapiro-Wilk test, moreover for 
variables where it is smaller the p-value is far from significant. 
• Note that the ANOVA residuals were already assessed by means of a normal probability plot 
(Appendix 6) and a plot of residuals versus fitted values (Appendix 7). 
• The non-parametric Wilcoxon signed rank test is used to test for a difference between each 
GMO feed and the control feed. Note that this test only uses data of these two feeds and that 
the test employs the within block difference between the GMO feed and the control feed. The 
p-value of the test is calculated by means of the wilcox.test() function in R which calculates exact 
probabilities. 
• The non-parametric Friedman test, which is applicable to a randomized block design, is used to 
test for overall differences between the five feeds. 
• Homogeneity of variance is assessed by means of Bartlett’s test and by means of Levene’s test 
both using the mean and the median. These test do not take blocking into account and basically 
compare the within feed variances. Note that homogeneity of variance was already assessed by 
means of a plot of residuals versus fitted values (Appendix 7). The p-value of the Levene test 
with the median is not reported since it is almost always larger that the p-value of the Levene 
test with the mean, and for variables where it is smaller the p-value is far from significant. Note 
that both analysis of variance and non-parametric tests require homogeneity of variance. 
• Finally, for each feeding group separately, normality was assessed by means of the Kolmogorov-
Smirnov test and the Shapiro-Wilk test. The p-value of the Kolmogorov-Smirnov test is always 
larger than 5% and is thus not reported. 
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For the oestrous cycle data (in group eCycle) the following variables were statistically analysed: 
• testing whether the probability of having an unfinished cycle is different between the feeds; 
Fisher’s exact test was used for this purpose; 
• testing whether the probability of having a cycle of 5 days is different between the feeds; 
Fisher’s exact test was used for this purpose; 
• testing whether the probability of having an irregular cycle is different between the feeds; this 
was done by means of logistic regression. 
4.3.2 Results 
Table 12 (males) and Table 13 (females) present the results of the t-tests, of Dunnett’s tests and of 
Wilcoxon tests for the 79 variables divided in ten groups. For ease of interpretation results are 
expressed as means and coefficients of variation on the original scale, rather than as means and 
standard deviations on the log scale. Note however that 95% confidence intervals on the ratio scale 
are given in Table 8 (males) and Table 9 (females). It can be seen that the relative precision of 
variables ranges from high precision, e.g. CV 1-3% for e.g. HGB, HCT, MCV, Ca, Cl, Na, to low 
precision, e.g. CV 40-175% for e.g. uLeu, uKeton, IL10, Eosinophils. 
Results of the t-test and Dunnett’s test for the difference tests, with 28 degrees of freedom for 
residual, are summarized by letters which indicate significance at 5% and at 1%. Results for the 
non-parametric Wilcoxon test, where each test only uses data for the specific GMO feed and the 
Control feed, are summarized in the same way. Exact p-values for these tests are given in Appendix 
14. In 62 cases (9.8% of the 632 comparisons) a difference was significant by at least one of the tests 
at the 5% level. On their own Dunnett’s test resulted in 17 significant differences (2.7%), the t-test 
resulted in 55 significant differences (8.7%), Wilcoxon’s test resulted in 26 significant differences 
(4.1%). Note that cells coloured red in Table 8 and Table 9, with confidence intervals for ratios, 
correspond to cells coloured red in Table 12 and Table 13 with letters t, T, d or D. 
Results of the Shapiro-Wilks test for normality and Bartlett’s and Levene’s test for homogeneity of 
variance are given in Appendix 15. The non-normality as indicated by the Shapiro-Wilks test for 
separate feeding groups is frequently significant. The graphs of cage means on the log scale in 
Appendix 5 indicate that significance of non-normality is mostly due to one outlying observation in a 
feeding group. 
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Table 12 Means and coefficient of variation (CV) for male rats. Means of GMO feeds which are significantly different from the Control feed are marked, 
with red background colouring, as follows: D: P<0.01 by Dunnett-test, d: P<0.05 by Dunnett-test, T: P<0.01 by t-test but not by Dunnett-test, 
t: P<0.05 by t-test but not by Dunnett-test, W: P<0.01 by Wilcoxon signed rank test, w: P<0.05 by Wilcoxon signed rank test. Note that 
Dunnett- and t-tests are based on a ANOVA with 5 treatment groups. 
Weights Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
BodyWeight 439.7 6.8 462.0 8.4 t 448.9 6.5  435.3 5.7  458.2 10.7  
growthRate 0.145 17.0 0.136 12.0  0.134 20.4  0.146 23.4  0.144 11.9  
FeedMean 19.99 5.8 20.20 8.2  20.04 4.9  18.53 3.3 DW 19.79 8.9  
Haematology Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
WBC 9.100 21.1 8.850 17.8  9.419 17.3  9.750 12.5  9.575 10.9  
RBC 7.790 3.8 7.768 5.6  7.768 3.4  7.672 4.6  7.829 2.6  
HGB 14.64 2.8 14.72 2.0  14.72 3.0  14.36 3.8  14.84 1.2  
HCT 42.36 2.8 42.84 4.6  43.05 3.3  42.40 3.8  43.16 2.0  
MCV 54.41 2.0 55.25 2.6  55.44 2.1  55.36 2.5  55.14 1.1  
MCH 18.82 2.5 18.74 2.8  18.97 3.6  18.76 4.2  18.96 2.4  
MCHC 34.57 0.8 33.90 2.8 t 34.22 2.3  33.87 1.7 tw 34.38 2.2  
PLT 842.5 8.9 792.1 15.1  861.6 14.5  851.0 9.7  847.1 13.6  
LYMR 73.02 5.1 72.49 6.9  70.93 8.3  71.97 4.7  73.42 6.9  
LYMA 6.644 23.3 6.419 19.3  6.681 20.0  7.000 10.0  7.037 15.4  
diffWBC Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
Lymphocytes 71.38 9.0 68.09 9.5  65.84 8.9 t 69.81 9.4  70.59 8.9  
Neutrophils 25.69 25.6 28.84 24.3  30.53 16.9 t 26.75 25.5  26.38 25.0  
Monocytes 1.500 30.9 1.656 26.7  1.781 51.7  1.531 26.8  1.312 31.8  
Eosinophils 1.438 40.3 1.406 51.1  1.844 71.7  1.906 47.0  1.719 45.6  
ClinChem Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
ALP 1.252 11.3 1.280 13.9  1.273 10.7  1.246 10.2  1.439 13.2 t 
ALT 0.563 7.1 0.572 10.6  0.550 13.9  0.501 11.5 tw 0.557 14.3  
AST 2.400 24.9 2.300 20.6  2.226 16.2  2.121 17.8  2.218 20.3  
BIL 7.300 27.0 7.075 13.8  6.919 6.1  7.156 11.4  6.481 5.3  
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ALB 36.41 2.2 36.65 4.8  36.89 2.1  37.80 2.6 dTw 36.38 3.6  
TP 64.39 1.7 65.11 3.6  64.99 1.7  66.22 2.5 dT 64.60 2.1  
Glu 5.381 15.8 5.337 15.3  5.018 13.7  5.153 6.9  5.491 9.6  
CHOL 2.047 11.2 2.006 13.5  2.022 10.8  1.936 10.0  2.041 8.5  
TAG 1.021 24.6 1.104 12.8  1.051 31.3  1.028 30.5  1.087 35.9  
Crea 40.13 5.2 41.55 11.5  40.82 8.8  43.79 10.6 t 41.94 9.9  
Urea 5.135 6.3 4.899 11.2  4.987 5.6  4.882 8.9  4.965 10.0  
cHGB 69.73 66.1 61.09 33.7  58.42 21.8  52.57 29.5  49.35 27.4  
Ca 2.402 1.7 2.400 1.2  2.406 2.3  2.414 1.9  2.392 1.5  
Cl 102.1 1.3 101.8 1.2  101.8 1.0  102.2 0.7  102.1 1.2  
K 4.987 4.5 5.087 7.2  5.250 3.9 t 5.225 5.9  5.106 4.8  
Na 144.8 1.1 144.9 1.0  145.3 0.8  145.6 0.8  145.2 1.0  
P 2.374 13.1 2.443 7.9  2.499 6.1  2.408 6.5  2.313 7.7  
Urine Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
uVol 19.25 18.6 19.12 28.9  22.31 32.0  21.12 40.7  19.19 26.5  
uVolW 4.595 20.7 4.306 26.9  5.171 32.6  5.051 39.7  4.389 28.1  
uLeu 28.12 127.4 20.31 65.3  31.25 109.0  26.56 134.1  18.75 50.4  
uOsmoll 489.0 30.2 473.7 19.9  447.5 24.2  455.4 30.5  480.3 18.8  
uKeton 0.419 73.9 0.781 52.5 w 0.750 123.4  0.531 121.8  0.312 175.0  
upH 7.125 4.2 7.000 5.7  6.875 1.9 t 6.938 4.6  6.750 2.8 dTw 
Organs Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
Kidney 0.521 7.2 0.524 5.4  0.537 5.4  0.548 6.9  0.516 7.9  
Spleen 0.179 8.2 0.186 5.6  0.177 9.3  0.188 7.8  0.181 8.1  
Liver 2.157 4.7 2.186 6.0  2.238 5.6  2.242 4.5  2.167 1.8  
AdrenGl 0.0140 9.1 0.0131 15.4  0.0131 11.3  0.0128 11.6  0.0131 11.0  
Heart 0.232 2.8 0.242 3.6 w 0.239 5.9  0.239 6.2  0.231 5.7  
Thymus 0.091 13.7 0.096 17.4  0.096 17.5  0.104 17.7 tw 0.096 17.3  
Testis 0.808 10.3 0.802 6.8  0.819 4.6  0.834 6.5  0.806 7.8  
Epididymis 0.267 8.9 0.262 4.3  0.279 7.1  0.274 5.9  0.272 11.0  
Brain 0.493 8.4 0.481 7.0  0.507 4.1  0.512 6.1  0.494 11.0  
Immunology Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
Granulocytes 73.80 17.7 77.50 12.4 t 73.57 16.8  73.69 19.3  73.55 16.1  
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RespirBurst 64.42 19.6 66.30 14.9  60.14 19.6  60.58 26.0  63.17 14.8  
Con 77166 27.7 78118 20.9  70681 21.4  73844 22.6  83659 21.5  
PHA 50436 35.3 51083 13.4  50736 20.7  47416 20.2  53347 15.0  
PWM 25656 59.6 36631 32.4  25415 55.7  25404 42.9  46487 63.4 t 
Medium 2370 38.1 2324 23.9  1944 30.9  1812 13.3  3003 46.9  
IprConA 34.82 25.0 37.43 19.7  40.15 15.2  41.48 34.1  34.65 43.3  
IprPHA 21.84 10.5 26.64 18.0  28.23 9.7  27.21 35.2  21.85 42.9  
IprPWM 10.48 29.0 15.28 21.6 d 12.71 26.4  13.95 40.8  15.14 30.0 t 
Cytokines Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
IL2 4082 22.9 5378 9.2 dT 4499 14.6  4477 21.4  5501 15.5 D 
IL4 28.71 84.4 14.62 34.9  10.87 6.9 t 11.32 15.3 t 14.06 14.2  
IL10 10265 80.0 9151 80.1  3256 48.5  3677 81.7  13753 94.7  
IL17A 183.6 66.0 145.5 32.6  119.3 39.9  98.0 46.7  197.9 59.4  
TNFa 17.91 40.5 25.07 6.9 dT 17.26 16.9  19.24 30.4  26.02 27.2 dT 
IFNg 14401 18.4 19549 23.3 dT 12162 14.3  13601 26.5  16342 23.9 t 
CellPhenotype Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
sp3 35.98 14.4 41.68 14.8  41.03 21.1  43.76 10.0 t 43.04 14.8 t 
sp3_4 21.44 17.9 24.18 21.2  26.18 25.6  25.63 15.7 t 26.40 23.7 t 
sp3_8 14.72 20.7 17.11 13.4  14.94 27.3  18.07 7.9 t 16.54 11.9  
sp3_45 24.90 4.3 25.57 1.9  24.70 5.5  24.58 5.4  25.23 2.9  
sp3_161 13.60 8.4 13.14 5.8  13.81 7.3  13.52 6.4  12.51 5.7  
ln3 57.78 7.0 59.17 6.6  53.89 20.9  52.69 23.9  54.56 19.2  
ln3_4 42.66 7.2 41.15 5.0  39.50 23.7  37.43 28.6  39.54 24.2  
ln3_8 15.47 8.5 17.85 11.5  15.02 13.0  16.21 16.5  15.58 7.8  
ln3_45 34.54 23.4 29.27 31.9 t 29.10 26.8  34.04 34.5  30.80 26.5  
ty3 18.41 25.3 18.65 20.0  19.29 12.5  19.98 11.4  20.23 14.5  
ty3_4 14.16 22.4 14.36 18.1  15.13 15.7  15.51 9.1  15.88 14.3  
ty3_8 7.925 21.6 8.390 23.6  8.240 8.3  8.350 12.7  8.995 18.0  
Hormone Control NK11- NK33- NK11+ NK33+ 
Males Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
Testosteron 2.579 34.3 2.784 59.1  1.974 56.6  3.026 63.7  2.170 25.6  
T3 0.750 8.1 0.816 16.7  0.745 12.1  0.748 12.6  0.805 10.0 w 
T4 55.16 8.6 54.03 10.0  48.65 7.5 dw 55.08 6.8  53.36 9.9  
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Table 13 Means and coefficient of variation (CV) for female rats. Means of GMO feeds which are significantly different from the Control feed are 
marked, with red background colouring, as follows: D: P<0.01 by Dunnett-test, d: P<0.05 by Dunnett-test, T: P<0.01 by t-test but not by 
Dunnett-test, t: P<0.05 by t-test but not by Dunnett-test, W: P<0.01 by Wilcoxon signed rank test, w: P<0.05 by Wilcoxon signed rank test. 
Note that Dunnett- and t-tests are based on a ANOVA with 5 treatment groups. 
Weights Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
BodyWeight 244.8 7.0 242.3 7.7  248.7 5.9  246.7 5.5  252.5 4.9  
growthRate 0.120 26.5 0.158 35.5 t 0.154 24.8 w 0.154 30.6  0.177 12.8 dTW 
FeedMean 14.31 9.6 12.96 11.8 d 13.91 8.4  13.77 5.1  14.03 6.5  
Haematology Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
WBC 5.519 26.7 5.369 18.0  6.063 19.2  4.862 14.4  5.425 23.3  
RBC 6.726 3.3 6.718 8.2  6.866 2.5  6.808 7.3  6.657 4.5  
HGB 13.72 3.3 13.56 7.6  14.11 1.3 w 13.84 5.9  13.58 4.8  
HCT 39.41 2.8 39.10 8.4  40.53 2.3  39.92 6.4  39.63 4.6  
MCV 58.66 2.4 58.23 3.1  59.06 1.8  58.72 2.8  59.59 2.2  
MCH 20.41 3.4 20.21 2.7  20.57 2.1  20.38 4.1  20.41 3.0  
MCHC 34.81 2.4 34.71 2.2  34.81 1.8  34.71 2.7  34.26 1.4  
PLT 901.9 12.6 824.6 17.5  901.4 10.1  813.0 12.3  903.6 10.4  
LYMR 75.17 7.7 75.06 4.7  77.48 4.5  76.59 6.4  77.11 6.4  
LYMA 4.225 32.4 4.037 17.2  4.688 19.4  3.713 18.5  4.150 23.4  
diffWBC Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
Lymphocytes 69.22 8.6 69.50 9.0  70.41 5.4  71.88 7.2  71.12 5.7  
Neutrophils 28.09 16.8 28.47 20.2  26.84 16.6  26.12 19.2  26.06 16.1  
Monocytes 1.531 49.7 1.125 58.2  1.438 57.9  1.125 33.6  1.250 45.4  
Eosinophils 1.156 104.0 0.906 77.9  1.312 71.8  0.875 117.3  1.562 62.7  
ClinChem Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
ALP 0.581 23.3 0.578 9.6  0.654 10.0  0.584 12.1  0.579 18.1  
ALT 0.470 12.9 0.417 10.3  0.525 23.0  0.453 29.6  0.424 19.1  
AST 2.299 29.0 2.225 15.5  2.326 11.0  2.205 24.1  2.366 18.7  
BIL 7.575 12.8 7.113 7.1  8.131 13.8  7.844 12.4  8.506 24.2  
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ALB 42.49 8.3 41.50 6.0  44.59 6.1  44.12 6.0  43.94 6.5  
TP 68.67 4.9 67.24 4.3  71.01 3.6  70.86 3.4  70.49 4.2  
Glu 5.188 6.8 5.117 23.1  4.404 15.4 dw 5.047 22.2  5.625 18.3  
CHOL 1.906 11.0 2.054 13.9  2.009 14.0  1.997 12.3  1.992 16.9  
TAG 0.524 24.7 0.621 31.9  0.647 13.4 tW 0.602 19.6  0.566 15.1  
Crea 40.91 5.9 42.01 6.8  42.86 9.3  40.75 12.4  41.90 13.5  
Urea 5.864 6.0 5.943 14.4  5.321 12.6  5.285 12.1  5.590 10.2  
cHGB 41.76 53.2 39.85 24.4  49.50 38.4  49.29 48.9  56.36 56.6  
Ca 2.472 2.8 2.454 1.4  2.489 1.6  2.495 2.1  2.494 2.0  
Cl 102.1 1.0 102.0 1.5  100.6 1.1 tw 101.6 1.1  102.1 1.8  
K 4.450 4.8 4.463 4.6  4.519 6.4  4.537 4.7  4.700 7.0  
Na 145.1 1.3 144.2 0.8  144.7 0.8  145.1 1.2  144.9 1.9  
P 2.040 11.3 1.964 11.7  2.153 16.8  1.931 11.1  1.956 11.4  
Urine Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
uVol 17.12 24.7 17.06 26.5  16.75 42.2  16.69 39.2  13.56 22.1  
uVolW 7.418 24.8 7.490 27.3  7.089 42.3  7.128 41.1  5.698 25.5  
uLeu 10.94 95.4 7.81 119.0  6.25 151.2  20.31 118.3  10.94 155.0  
uOsmoll 412.8 27.2 417.2 25.0  434.6 28.2  413.6 31.0  427.1 14.7  
uKeton 0.156 119.0 0.031 282.8  0.156 169.7  0.031 282.8  0.000 * t 
upH 6.625 4.0 6.438 4.5 w 6.500 3.6  6.438 4.0  6.469 2.5  
Organs Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
Kidney 0.598 8.5 0.570 8.7  0.570 8.0  0.579 5.8  0.581 4.3  
Spleen 0.245 7.2 0.225 12.4  0.245 9.0  0.217 10.0 dTw 0.245 7.4  
Liver 2.444 5.8 2.554 7.6  2.498 12.8  2.531 6.6  2.391 3.5  
AdrenGl 0.0312 10.5 0.0280 8.7 t 0.0283 6.2 t 0.0284 10.0 t 0.0292 5.8  
Heart 0.320 5.4 0.311 13.0  0.306 6.2 w 0.308 6.7  0.320 9.9  
Thymus 0.117 17.2 0.120 14.2  0.122 20.8  0.115 18.5  0.117 13.3  
Uterus 0.251 19.5 0.256 32.4  0.244 19.6  0.254 22.8  0.313 16.8  
Ovary 0.0381 6.9 0.0338 8.4 dw 0.0355 16.1  0.0362 7.8  0.0324 3.7 dTW 
Brain 0.840 6.8 0.854 4.7  0.833 5.4  0.830 6.3  0.817 2.9  
Immunology Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
Granulocytes 76.77 4.1 70.96 8.3 t 77.69 4.2  73.50 4.3  73.06 5.0  
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RespirBurst 56.32 23.5 52.40 3.4  54.54 11.2  52.28 22.3  57.86 13.5  
Con 51683 37.3 61830 28.7  54694 46.2  65130 39.7  63123 33.0  
PHA 29498 44.4 36438 47.0  27484 57.3  34743 30.3  36871 22.2  
PWM 18769 80.4 23672 26.3  18101 53.4  22491 46.0  25289 62.6  
Medium 1429 38.1 1685 13.0  1422 45.4  1788 29.8  1870 37.2  
IprConA 38.00 26.3 37.47 29.0  37.84 20.8  36.62 15.8  35.99 13.7  
IprPHA 21.40 26.0 21.77 42.8  19.88 28.0  21.70 36.0  21.66 28.4  
IprPWM 11.38 47.7 13.62 27.5  12.69 20.2  12.18 21.3  13.20 42.1  
Cytokines Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
IL2 3821 15.2 4491 6.3  3240 39.1  3936 6.2  3434 38.4  
IL4 14.16 14.3 12.13 17.6  9.53 50.0  25.94 55.2  11.11 62.9  
IL10 10919 105.0 9553 102.9  4401 60.6  11809 72.1  8175 143.3  
IL17A 201.4 21.5 115.3 24.4 dT 103.2 53.6  184.6 27.0  104.6 66.1 t 
TNFa 19.85 26.2 15.62 6.9  12.20 48.0  21.70 4.7  13.71 46.8  
IFNg 12364 37.7 9788 21.4  8656 63.6  13476 14.7  9123 69.0  
CellPhenotype Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
sp3 37.10 5.8 41.81 9.0  38.60 12.5  39.74 14.8  41.06 8.7  
sp3_4 20.61 6.9 24.91 15.9  21.71 25.8  24.00 21.3  23.20 12.1  
sp3_8 16.12 5.6 15.67 10.0  15.53 4.8  15.19 11.1  17.16 11.6  
sp3_45 25.56 1.4 25.68 2.5  25.53 2.9  25.06 1.0  25.68 3.4  
sp3_161 11.15 5.5 10.88 2.8  10.97 5.2  10.86 1.0  11.28 9.6  
ln3 61.37 4.2 61.10 7.7  61.87 4.5  61.86 6.4  64.77 4.4  
ln3_4 44.76 5.5 45.52 9.4  45.08 8.9  46.07 8.6  46.96 5.9  
ln3_8 17.00 3.6 16.04 7.9  16.91 10.3  16.25 3.6  18.07 10.5  
ln3_45 20.39 33.8 25.62 36.1  21.75 35.4  22.03 37.5  18.39 29.9  
ty3 20.05 20.5 19.65 17.8  20.00 10.4  20.63 23.2  19.91 17.9  
ty3_4 15.24 24.6 15.27 19.8  15.77 11.9  15.40 24.6  14.80 16.7  
ty3_8 8.715 28.6 7.940 21.5  8.325 31.3  8.645 27.8  8.110 28.7  
Hormone Control NK11- NK33- NK11+ NK33+ 
Females Mean CV Mean CV Sig Mean CV Sig Mean CV Sig Mean CV Sig 
Estradiol 7.740 58.3 4.975 69.4 t 4.634 29.2 tw 5.044 41.1 tw 4.644 27.8 tW 
T3 0.757 21.4 0.766 15.2  0.690 11.9  0.731 18.1  0.635 18.8  
T4 34.20 23.2 31.02 27.4  33.97 33.4  37.79 24.0  25.41 33.4 tw 
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For the oestrous cycle data (in group eCycle) the following was found.  
The duration of the first oestrous cycle is mostly 5 days with the exception of the following four 
female rats: 114 (6 days, NK11-), 116 (6 days, NK11-), 130 (3 days, NK33+) and 162 (unfinished, 
NK11+). According to Fishers exact test 2 out of 16 with a different cycle duration (NK11-) is not 
significantly different from 0 out of 16 (Control), with p-value equal to 0.484. So there is no indication 
that the duration of the first cycle is different between the GMO feeding groups and the control 
group. Note that Fishers exact test assumes that animals (even within a cage) have independent 
cycle duration. 
The duration of the second oestrous cycle is given in Table 14; there are many rats with an unfinished 
cycle. The two NK11- rats with a 6 days second cycle are different from the ones with a first cycle of 
6 days. Pairwise testing whether the probability of an unfinished second cycle is equal, again with 
Fishers Exact test and assuming that animals (even within a cage) have independent cycle duration, 
reveals that there are significant differences between Control and NK11+ (p=0.009), between NK11- 
and NK33- (p=0.032), and between NK11- and NK11+ (p=0.003). There is also an indication of a 
difference between NK11+ and NK33+ (p=0.054). Testing, in the same way, whether the probability 
of a second cycle of 5 Days is equal results in less significant results: there is only a significant 
difference between Control and NK11+ (p=0.023) and an indication for a difference between NK11- 
and NK11+ (p=0.054). 
Table 14 Number of rats in each feeding group with specified length of the second oestrous cycle. 
Group unfinished 3 Days 4 Days 5 Days 6 Days 
Control 6 - 1 9 - 
NK11- 5 1 - 8 2 
NK33- 12 - - 4 - 
NK11+ 14 - - 2 - 
NK33+ 8 - 1 7 - 
 
The number of irregular cycles out of two cycles follows a binomial distribution with binomial total 2 
and probability π, and the question is whether these probabilities are different between groups. This 
was tested with logistic regression, again assuming that rats are independent with respect to 
irregularity of cycles, by fitting the Block + Group model. Pairwise differences between groups were 
tested by a likelihood ratio test, giving mean probabilities and p-values for differences with the 
Control in Table 15. There is some indication (p=0.061) that the Control group has a larger probability 
of an irregular cycle than the NK33- and NK33+ groups. There are no significant differences between 
the GMO feed groups. 
Table 15 Estimated probabilities of having an irregular oestrous cycle and p-values for differences 
between the control feed and the GMO feeds resulting from a logistic regression. 
Group Mean Probability p-value 
Control 0.2188 - 
NK11- 0.1250 0.307 
NK33- 0.0625 0.061 
NK11+ 0.1250 0.307 
NK33+ 0.0625 0.061 
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4.4 Standardised effect sizes 
4.4.1 Method 
EFSA (2011b) defines the standardised effect size (SES) as the effect size measured in SD units, where 
SD is the standard deviation among experimental units. We will assume that in a randomised block, 
experiment like the current G-TwYST study, SD refers to the pooled residual variation. The use of SES 
in EFSA (2011b) was in the context of determination of sample size and power: ‘If experience from 
previous toxicity tests shows an effect size of, say, one SD or less is of little toxicological relevance 
then this can be used to determine sample size in new situations’ (EFSA 2011b). Zeljenková et al 
(2014) followed this example and, without further toxicological motivation, ‘assumed that an SES of 
1.0 SD or less is unlikely to be of toxicological importance’. Consequently, all results of the GRACE 
studies have been reported as confidence intervals on the SES scale (Zeljenková et al, 2014, 2016, 
Schmidt et al 2015, 2017). In this section the same SES graphs are calculated for comparability 
between GRACE and G-TwYST. 
Standardized effect sizes (SES), again using the residual standard error with 28 degrees of freedom, 
and their exact 95% confidence intervals were calculated. This employed the conf.limits.nct() 
function in the MBESS R-package, see section 3 in Kelley (2007). Note that, since the calculated SES 
confidence interval is exact, the SES interval does not contain zero if and only if the p-value of the 
t-test is smaller than 5%. 
4.4.2 Results 
SES intervals were calculated for all 79 variables. Results for the four treatment groups, separately 
for males and females, are given in Figure 21 to Figure 24. It can be noted that almost all intervals 
(616 out of 632, i.e. 97.5%) extend outside the +/-1 SD limits. 
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Figure 21 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK11- and NK33- versus the control feed. 
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Figure 22 Confidence intervals for Standardized Effect Sized (SES) for male rats for GMO feeds 
NK11+ and NK33+ versus the control feed. 
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Figure 23 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK11- and NK33- versus the control feed. 
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Figure 24 Confidence intervals for Standardized Effect Sized (SES) for female rats for GMO feeds 
NK11+ and NK33+ versus the control feed. 
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4.5 Factorial analysis 
4.5.1 Method 
The purpose of this oral toxicity study is to assess the effects of GM maize NK 603 when fed to rats 
for a period of 90 days at an incorporation rate of 11% and 33% in the feed. Table 16 lists the maize 
type and incorporation rate of the 5 diets as well as the number of animals used for every diet.  
Table 16  Diets used in the 90-day feeding trial study 1 with GM inclusion rates 11% and 33%. 
Group 
Isogenic maize  
(% of diet) 
NK603 only  
(% of diet) 
NK603 + Roundup 
(% of diet) 
No. of Males No. of Females 
Control 33 0 0 16 16 
NK11- 22 11 0 16 16 
NK33- 0 33 0 16 16 
NK11+ 22 0 11 16 16 
NK33+ 0 0 33 16 16 
 
The structure of the G-TwYST study is a 2 by 2 factorial design for the GM feeding groups with factors 
GM inclusion rate (IR, 11% or 33%) and use of Roundup (RU, -  or +), with an added control for the 
non-GM control group. This structure allows a more sensitive analysis, integrating over the five dose 
group, according to the model: 
𝑦𝑦0𝑊𝑊 = 𝜇𝜇 + 𝛿𝛿𝑊𝑊 + 𝜖𝜖𝑖𝑖𝑖𝑖𝑊𝑊   for data in the Control (non-GM) group (i = 0) 
𝑦𝑦𝑖𝑖𝑖𝑖𝑊𝑊 = 𝜇𝜇 + 𝐺𝐺𝐺𝐺 + 𝐼𝐼𝑅𝑅𝑖𝑖 + 𝑅𝑅𝑈𝑈𝑖𝑖 + 𝑖𝑖𝑛𝑛𝑡𝑡𝑖𝑖𝑖𝑖 + 𝛿𝛿𝑊𝑊 + 𝜖𝜖𝑖𝑖𝑖𝑖𝑊𝑊 for data in GM groups, 𝑖𝑖 = 1,2; 𝑗𝑗 = 1,2. 
In this model the stochastic terms are 𝛿𝛿𝑊𝑊  for block effects and 𝜖𝜖𝑖𝑖𝑖𝑖𝑊𝑊 for residual effects. The fixed term 
𝐺𝐺𝐺𝐺 estimates the difference between the four GM groups (averaged) and the control. This is only a 
useful estimate if the other three fixed terms can be assumed to be zero. The main effect 𝐼𝐼𝑅𝑅2 − 𝐼𝐼𝑅𝑅1 
estimates the difference between the groups with GM inclusion rates 33% and 11%, and similarly, 
the main effect 𝑅𝑅𝑈𝑈2 − 𝑅𝑅𝑈𝑈1 estimates the difference between the groups with and without Roundup. 
These main effects are only useful when there is no interaction between GM inclusion rate and 
Roundup. 
4.5.2 Results 
The significance results from fitting the factorial model to the 79 variables are given in Table 18. The 
ratios for the significant cases are shown in Table 19 and Table 20. 
As an example, consider the results for growthRate, HGB and PLT for females; the means, after the 
usual log transformation, for these variables are given in Table 17. For growthRate the means suggest 
that there is an interaction between GM inclusion rate and Roundup, because there is hardly an 
effect of GM inclusion rate for RoundUp-, while there appears to be an effect of GM inclusion rate for 
RoundUp+. However this interaction is, according to Table 18, not significant with p-value 0.301. The 
main GMO effect, i.e. comparing the mean of the four GMO feeds, which equals 0.161, to the control 
feed, is however very significant with p-value 0.008. The corresponding ratio equals exp(0.161 – 
0.120) = 1.04, and this ratio is given in Table 20. 
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For HGB there is a significant interaction (p=0.026, Table 18) between GM inclusion rate and 
RoundUp with, for RoundUp- increasing means when GM inclusion rate is increased, and for 
RoundUp+ decreasing values when GM inclusion rate is increased (Table 17). This implies that the 
effect of GM inclusion rate depends on whether or not RoundUp is applied. In Table 20 the ratios for 
HGB are expressed relative to the NK11- feeding group.  
For PLT there is not a significant interaction because the effect of GM inclusion rate, see Table 17, is 
very similar for RoundUp- (difference equals 0.09) and RoundUp+ (difference equals 0.11,). The mean 
effect across the two roundup treatment equals 0.10, and this is significantly different from zero 
(p=0.035, Table 18). The corresponding ratio in Table 20 equals exp(0.10) = 1.10. 
Table 17  Means for three example variables in females which exhibit significant main effects or a 
significant interaction between GM inclusion rate of the GMO feed (IR-11 and IR-33) and 
application of RoundUp (-/+) when applying the factorial model.  
 growthRate HGB PLT 
Control IR-11 IR-33 Control IR-11 IR-33 Control IR-11 IR-33 
Control 0.120 - - 2.62 - - 6.79 - - 
RoundUp- - 0.158 0.154 - 2.60 2.65 - 6.70 7.79 
RoundUp+ - 0.154 0.177 - 2.63 2.61 - 6.69 6.80 
 
The p-values in Table 18 can be summarized as follows. In 17 cases (11% of all 158 cases) there was a 
significant difference at the 5% level between GM and non-GM. In 26 cases (16% of all 158 cases) 
there was a significant interaction term at the 5% level. In these latter cases the main effects should 
not be used for assessing effects of GM inclusion rate or Roundup. Among the remaining 132 cases, 
i.e. where the interaction is not significant, there were 10 cases (8%) with a significant differences 
between GM inclusion rates, and 3 cases (2%) with a significant difference between the GMO feeds 
with and without roundup.  
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Table 18  P values for significance of effects obtained with the factorial model. P-values smaller 
than 0.01/0.05 have a gold/yellow background. 
Response Males Females 
Weights GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
BodyWeight 0.198 0.558 0.220 0.032 0.483 0.093 0.257 0.891 
growthRate 0.574 0.832 0.240 0.968 0.008 0.463 0.440 0.301 
FeedMean 0.756 0.118 0.009 0.145 0.272 0.034 0.144 0.273 
Haematology GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
WBC 0.542 0.676 0.307 0.495 0.982 0.135 0.120 0.857 
RBC 0.779 0.425 0.923 0.549 0.869 0.927 0.639 0.246 
HGB 0.918 0.051 0.276 0.052 0.852 0.390 0.503 0.026 
HCT 0.422 0.316 0.800 0.636 0.682 0.353 0.964 0.190 
MCV 0.056 0.999 0.811 0.625 0.691 0.115 0.343 0.997 
MCH 0.882 0.219 0.974 0.940 0.956 0.405 0.987 0.491 
MCHC 0.070 0.075 0.742 0.712 0.506 0.485 0.257 0.263 
PLT 0.742 0.518 0.587 0.231 0.412 0.035 0.970 0.818 
LYMR 0.666 0.823 0.471 0.327 0.433 0.342 0.734 0.532 
LYMA 0.681 0.735 0.212 0.769 0.832 0.109 0.177 0.704 
diffWBC GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
Lymphocytes 0.165 0.593 0.059 0.328 0.462 0.921 0.430 0.633 
Neutrophils 0.178 0.720 0.065 0.525 0.569 0.708 0.418 0.816 
Monocytes 0.704 0.401 0.161 0.429 0.183 0.525 0.757 0.785 
Eosinophils 0.550 0.486 0.306 0.514 0.808 0.090 0.998 0.364 
ClinChem GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
ALP 0.323 0.076 0.243 0.077 0.484 0.325 0.214 0.205 
ALT 0.375 0.418 0.096 0.045 0.508 0.264 0.302 0.128 
AST 0.206 0.810 0.372 0.509 0.810 0.272 0.889 0.938 
BIL 0.531 0.196 0.554 0.363 0.530 0.043 0.198 0.392 
ALB 0.198 0.122 0.369 0.024 0.274 0.105 0.256 0.073 
TP 0.087 0.059 0.396 0.087 0.246 0.075 0.104 0.034 
Glu 0.776 0.904 0.383 0.115 0.355 0.763 0.021 0.018 
CHOL 0.574 0.272 0.780 0.562 0.278 0.756 0.753 0.978 
TAG 0.640 0.994 0.460 0.378 0.050 0.696 0.463 0.199 
Crea 0.166 0.312 0.160 0.652 0.650 0.491 0.357 0.855 
Urea 0.242 0.593 0.866 0.895 0.177 0.552 0.415 0.055 
cHGB 0.299 0.736 0.170 0.776 0.411 0.342 0.400 0.669 
Ca 0.914 0.472 0.996 0.234 0.507 0.279 0.153 0.268 
Cl 0.716 0.923 0.304 0.926 0.256 0.321 0.262 0.040 
K 0.068 0.703 0.939 0.083 0.329 0.262 0.173 0.596 
Na 0.293 0.937 0.496 0.328 0.499 0.858 0.313 0.494 
P 0.504 0.785 0.168 0.243 0.667 0.257 0.266 0.386 
Urine GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
uVol 0.960 0.816 0.964 0.467 0.369 0.411 0.379 0.617 
uVolW 0.874 0.873 0.829 0.283 0.335 0.306 0.305 0.647 
uLeu 0.879 0.735 1.000 1.000 0.633 0.290 0.290 0.523 
uOsmoll 0.617 0.959 0.735 0.367 0.854 0.624 0.863 0.912 
uKeton 0.760 0.255 0.111 0.929 0.034 0.540 0.198 0.198 
upH 0.021 0.079 0.284 0.719 0.092 0.581 0.854 0.854 
Organs GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
Kidney 0.502 0.498 0.986 0.113 0.199 0.911 0.511 0.955 
Spleen 0.532 0.092 0.493 0.794 0.141 0.003 0.538 0.594 
Liver 0.161 0.725 0.834 0.057 0.593 0.119 0.394 0.565 
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AdrenGl 0.095 0.629 0.791 0.772 0.013 0.507 0.477 0.801 
Heart 0.311 0.213 0.224 0.634 0.322 0.662 0.415 0.345 
Thymus 0.071 0.419 0.512 0.193 0.791 0.704 0.526 0.773 
Testis 0.646 0.768 0.648 0.225 - - - - 
Epididymis 0.493 0.422 0.747 0.219 - - - - 
Uterus - - - - 0.689 0.426 0.176 0.221 
Ovary - - - - 0.013 0.468 0.918 0.033 
Brain 0.548 0.664 0.391 0.014 0.712 0.214 0.132 0.710 
Immunology GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
Granulocytes 0.417 0.103 0.060 0.052 0.063 0.034 0.611 0.012 
RespirBurst 0.476 0.576 0.481 0.036 0.722 0.200 0.620 0.492 
Con 0.779 0.283 0.859 0.231 0.330 0.362 0.257 0.300 
PHA 0.483 0.264 0.493 0.243 0.406 0.399 0.108 0.192 
PWM 0.139 0.410 0.444 0.006 0.047 0.409 0.365 0.216 
Medium 0.780 0.175 0.480 0.035 0.132 0.270 0.084 0.133 
IprConA 0.552 0.867 0.526 0.282 0.992 0.684 0.921 0.909 
IprPHA 0.264 0.621 0.152 0.151 0.748 0.977 0.657 0.839 
IprPWM 0.004 0.581 0.726 0.040 0.151 0.917 0.515 0.752 
Cytokines GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
IL2 0.002 0.669 0.941 0.001 0.477 0.061 0.566 0.109 
IL4 0.006 0.931 0.917 0.030 0.963 0.147 0.252 0.081 
IL10 0.844 0.241 0.564 0.002 0.864 0.825 0.333 0.886 
IL17A 0.948 0.178 0.780 0.030 0.002 0.445 0.012 0.005 
TNFa 0.008 0.985 0.733 0.001 0.085 0.034 0.005 0.134 
IFNg 0.019 0.312 0.379 0.001 0.827 0.275 0.341 0.234 
CellPhenotype GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
sp3 0.009 0.249 0.068 0.549 0.086 0.552 0.991 0.122 
sp3_4 0.008 0.772 0.147 0.991 0.094 0.152 0.823 0.264 
sp3_8 0.055 0.007 0.027 0.269 0.736 0.106 0.307 0.044 
sp3_45 0.715 0.890 0.417 0.047 0.774 0.335 0.320 0.107 
sp3_161 0.329 0.553 0.149 0.015 0.609 0.290 0.573 0.487 
ln3 0.274 0.547 0.238 0.148 0.508 0.152 0.149 0.523 
ln3_4 0.119 0.900 0.247 0.277 0.500 0.848 0.305 0.621 
ln3_8 0.321 0.036 0.540 0.122 0.720 0.006 0.096 0.349 
ln3_45 0.028 0.610 0.077 0.362 0.477 0.061 0.082 0.917 
ty3 0.130 0.563 0.154 0.660 0.965 0.934 0.677 0.497 
ty3_4 0.091 0.401 0.097 0.591 0.777 0.850 0.385 0.426 
ty3_8 0.194 0.409 0.367 0.446 0.179 0.479 0.437 0.177 
Hormone GMO InclRate Roundup Interact GMO InclRate Roundup Interact 
Testosteron 0.241 0.094 0.372 0.743 - - - - 
betaEstr - - - - 0.007 0.906 0.950 0.692 
T3 0.373 0.943 0.909 0.014 0.421 0.049 0.233 0.696 
T4 0.158 0.024 0.046 0.221 0.390 0.084 0.909 0.023 
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Table 19 Ratios for significant variables at the 5% level in the factorial analysis for males. Main 
effects are “GM vs Contrl” (ratio of the mean of the four GM feeds vs the control feed), 
“33 vs 11” (ratio of the two GM feeds with 33% GM inclusion rate vs the two feeds with 
11% GM inclusion rate) and “+RU vs -RU“ (ratio of the two GM feeds with roundup vs 
the two feeds without roundup). The interaction ratios are scaled such that NK11- 
equals 1. The InclRate and RndUp main effects are only given when the interaction is not 
significant. 
 
Males 
Group Variable 
GM vs 
Contrl 
33 vs 
11 
+RU vs 
-RU 
Interaction 
NK11- NK33- NK11+ NK33+ 
Weights BodyWeight - - - 1.00 0.97 0.94 0.99 
Weights FeedMean - - 0.95 - - - - 
ClinChem ALT - - - 1.00 0.95 0.87 0.97 
ClinChem ALB - - - 1.00 1.01 1.03 0.99 
Urine upH 0.79 - - - - - - 
Organs Brain - - - 1.00 1.06 1.06 1.02 
Immunology RespirBurst - - - 1.00 0.90 0.89 0.95 
Immunology PWM - - - 1.00 0.71 0.70 1.27 
Immunology Medium - - - 1.00 0.90 0.82 1.30 
Immunology IprPWM 1.35 - - 1.00 0.80 0.86 0.98 
Cytokines IL2 1.25 - - 1.00 0.83 0.81 1.02 
Cytokines IL4 0.70 - - 1.00 0.78 0.78 0.98 
Cytokines IL10 - - - 1.00 0.52 0.44 1.59 
Cytokines IL17A - - - 1.00 0.82 0.58 1.26 
Cytokines TNFa 1.35 - - 1.00 0.69 0.72 1.03 
Cytokines IFNg 1.30 - - 1.00 0.63 0.64 0.84 
CellPhenotype sp3 1.15 - - - - - - 
CellPhenotype sp3_4 1.17 - - - - - - 
CellPhenotype sp3_8 - 0.86 1.12 - - - - 
CellPhenotype sp3_45 - - - 1.00 0.97 0.96 0.99 
CellPhenotype sp3_161 - - - 1.00 1.05 1.03 0.95 
CellPhenotype ln3_8 - 0.91 - - - - - 
CellPhenotype ln3_45 0.87 - - - - - - 
Hormone T3 - - - 1.00 0.92 0.92 0.99 
Hormone T4 - 0.94 1.06 - - - - 
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Table 20 Ratios for significant variables at the 5% level in the factorial analysis for females. Main 
effects are “GM vs Contrl” (ratio of the mean of the four GM feeds vs the control feed), 
“33 vs 11” (ratio of the two GM feeds with 33% GM inclusion rate vs the two feeds with 
11% GM inclusion rate) and “+RU vs -RU“ (ratio of the two GM feeds with roundup vs 
the two feeds without roundup). The interaction ratios are scaled such that NK11- 
equals 1. The InclRate and RndUp main effects are only given when the interaction is not 
significant. 
 
Females 
Group Variable 
GM vs 
Contrl 
33 vs 
11 
+RU vs 
-RU 
Interaction 
NK11- NK33- NK11+ NK33+ 
Weights growthRate 1.04 - - - - - - 
Weights FeedMean - 1.06 - - - - - 
Haematology HGB - - - 1.00 1.04 1.02 1.00 
Haematology PLT - 1.11 - - - - - 
ClinChem BIL - 1.10 - - - - - 
ClinChem TP - - - 1.00 1.06 1.05 1.05 
ClinChem Glu - - - 1.00 0.87 1.00 1.11 
ClinChem TAG 1.17 - - - - - - 
ClinChem Cl - - - 1.00 0.99 1.00 1.00 
Urine uKeton 0.78 - - - - - - 
Organs Spleen - 1.11 - - - - - 
Organs AdrenGl 0.91 - - - - - - 
Organs Ovary 0.90 - - 1.00 1.05 1.08 0.97 
Immunology  Granulocytes - - - 1.00 1.11 1.05 1.04 
Immunology PWM 1.49 - - - - - - 
Cytokines IL17A 0.63 - - 1.00 1.33 1.96 1.26 
Cytokines TNFa - 0.84 1.30 - - - - 
CellPhenotype sp3_8 - - - 1.00 0.98 0.96 1.09 
CellPhenotype ln3_8 - 1.08 - - - - - 
Hormone betaEstr 0.64 - - - - - - 
Hormone T3 - 0.88 - - - - - 
Hormone T4 - - - 1.00 1.08 1.34 0.79 
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4.6 Correlation analysis 
4.6.1 Method 
For single variables the difference between a GM feed group and the control group is quantified by 
the ratio of the responses. These can then be compared to given limits (as in Figure 18 and Figure 19) 
or to limits calculated from historical data (as in Figure 9 - Figure 16, or rescaled, as in Figure 5 - 
Figure 8). 
For a toxicological interpretation it may be helpful to see results for variables that simultaneously 
relate to the same pathological endpoint. Bivariate plots were prepared showing the patterns for 
each pair for three variables related to liver disorder (relative liver weight, ALP, CHOL) and three 
variables related to kidney disorder (relative kidney weight, Urea, Crea). The eight points in each 
graph are based on the cage means in the eight blocks of the study. 
For comparison, the proposed target effect sizes of Hong et al (2017) are included in the plots as 
horizontal and vertical lines (together with lines at ratio 1 for reference). It can be noted that similar 
plots could have been made using the equivalence limit scaled differences (ELSDs) as presented in 
Figure 5 - Figure 8. 
4.6.2 Results 
The correlation plots for three liver-related and three kidney-related variables in males and females 
are shown in Figure 25 - Figure 28. In most cases there appears to be no clear correlation. Exceptions 
are a significant positive correlation for liver weight versus CHOL for NK33+ in females (corr = 0.925, 
p-value = 0.001), and for NK33- in females significant negative correlations for kidney weight versus 
Urea (corr = -0.754, p-value=0.031) and Crea (corr = -0.719, p-value=0.045). Note that in the latter 
case there is also a positive correlation for Urea versus Crea (corr = 0.881, p-value = 0.004). 
Exceedance of a threshold level (kidney weight in NK33- Males, liver weight in NK33- Females) is not 
accompanied by exceedance of the threshold in the other plotted variable. 
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Figure 25 Pairwise results for variables with set target effect sizes related to liver damage in 
Males. In each row there are four graphs corresponding to the four GM feed groups. 
Points represent the ratio of the cage mean for the GM group vs. the cage mean for the 
control feed in the eight blocks in the study. Horizontal and vertical lines represent a 
ratio of 1 and the target effect sizes from Hong et al (2017). 
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Figure 26 Pairwise results for variables with set target effect sizes related to kidney damage in 
Males. In each row there are four graphs corresponding to the four GM feed groups. 
Points represent the ratio of the cage mean for the GM group vs. the cage mean for the 
control feed in the eight blocks in the study. Horizontal and vertical lines represent a 
ratio of 1 and the target effect sizes from Hong et al (2017). 
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Figure 27 Pairwise results for variables with set target effect sizes related to liver damage in 
Females. In each row there are four graphs corresponding to the four GM feed groups. 
Points represent the ratio of the cage mean for the GM group vs. the cage mean for the 
control feed in the eight blocks in the study. Horizontal and vertical lines represent a 
ratio of 1 and the target effect sizes from Hong et al (2017). 
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Figure 28 Pairwise results for variables with set target effect sizes related to kidney damage in 
Females. In each row there are four graphs corresponding to the four GM feed groups. 
Points represent the ratio of the cage mean for the GM group vs. the cage mean for the 
control feed in the eight blocks in the study. Horizontal and vertical lines represent a 
ratio of 1 and the target effect sizes from Hong et al (2017). 
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5 Summary and discussion 
In this report the data from G-TwYST study B have been analysed following six approaches. For 
comparisons between a GM feeding group and the control feed for a single variable, these 
approaches were two forms of equivalence analysis (4.1, 4.2), the traditional approach focusing on 
significant differences (4.3), and the standardised effect size (SES) approach (4.4). In addition, a 
factorial analysis (4.5) and a correlation analysis (4.6) allowed some limited forms of integration over 
dose groups or variables, respectively. 
Among the two forms of equivalence analysis, the approach with given external equivalence limits 
(4.2) is the most simple one. It could be preferred if toxicologists were able to set external 
equivalence limits for all relevant variables based on their expert knowledge. In the current report it 
was applied to nine variables, for which Hong et al (2017) recently proposed targeted effect sizes. 
Obviously, the uncertainty in setting these targeted effect sizes is not accounted for in the 
equivalence analysis using these fixed limits. 
However, external equivalence limits are often not available, and toxicologists notice many 
uncertainties about the impact of toxicological effects. Moreover, they find it often difficult to come 
to a conclusion on such equivalence limits. For such cases, the equivalence analysis which bases 
equivalence on historical non-GM data (4.1) may be an attractive alternative. This approach assumes 
that test facilities perform whole-food studies with rodents on a routine basis, such that variations 
between non-GM foods and between experimental units which are seen in historical studies have a 
relevance for the current study. In the current report, the approach could be applied to 42 variables, 
which were also observed in five preceding studies in the same test facility in the GRACE project. Van 
der Voet et al (2017) discusses this new method which was developed in the G-TwYST project. 
Given tentative settings for regulatory parameters, equivalence was established in 97% of cases 
(70/72) for the approach with external equivalence limits and for 94% of cases (301/320) for the 
approach based on the historical GRACE data. The regulatory parameters are the testing level (set at 
5%) for all approaches, and two parameters for the new G-TwYST equivalence approach: the desired 
power (set at 95%) and the minimum sample size per group (set at 8 experimental units). Note that 
test results could be different if these parameters were chosen differently. 
In all cases where equivalence was not established by means of the statistical test, the median 
estimate was still in the equivalence region. Therefore, in the terminology of EFSA (2011a), these 
cases are still classified as ‘equivalence more likely than lack of equivalence’.  
As noted by EFSA (2011b), separate analysis of many endpoints, most of which are not expected to 
differ between treatment groups, results in a large number of statistical tests. This will lead to the 
issue of multiple testing (multiplicity). The proportion of non-significant equivalence tests (3% or 6%) 
was close to the nominal level of the tests (which was set at 5%). In this report, we have not tried to 
adapt equivalence tests for multiplicity. However, it should be pointed out that a recently proposed 
approach to adjusting for multiplicity based on the False Discovery Rate (FDR) is not appropriate. 
Hong et al (2017) used adjusted p values using the FDR method for multiplicity adjustment. This 
means that effectively most p values are much larger (indicating less significant differences) than in a 
standard unadjusted analysis. This may explain why they report that ‘no treatment-related 
differences were observed’, although there were some 150 continuous endpoints in total. This 
complete absence of statistically significant differences is very much at odds with what is commonly 
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found (e.g. in the GRACE, G-TwYST, and GMO90+ studies). Indeed, the absence of significant 
differences in Hong et al (2017) could be a direct consequence of using the FDR adjustment. It is 
doubtful whether the use of the FDR-correction makes sense in food safety testing (EFSA 2010). It 
controls false discoveries, and is therefore connected to difference testing, where false positives are 
considered as error of the first kind. i.e. one wants to have a small probability of erroneously 
reporting a difference. In the context of equivalence testing the statistical hypotheses are reversed, 
and false negatives are the error of the first kind, i.e. one wants to have a small probability of 
erroneously reporting equivalence. Consequently, the FDR concept is addressing the wrong type of 
error. 
Classical analysis following OECD guidance is only focusing on finding differences, not equivalences. If 
performed using t-tests after applying an ANOVA model, there were 55 significant differences at the 
5% significance level. This is 9% of the total number of comparisons (632), and higher than the 
nominal 5% level that could be expected. The scheme advocated by OECD contains several 
adaptations. First, a multiplicity correction by using Dunnett’s test rather than the straight-forward 
t-test is proposed for the fact that four groups are compared at the same time to the control group. 
Thus, applying Dunnett’s test the number of significant cases at the 5% significance level was 
reduced to 17 (3% of all comparisons, i.e. similar to the nominal error level). However, a multiplicity 
correction may be wrong for the same reason why the FDR method was wrong: if we are primarily 
interested in safety and equivalence, then the roles of the statistical hypotheses are reversed, and 
corrections as used in Dunnett’s test address the wrong type of error. 
OECD (2012) also proposes non-parametric tests in case of non-normality or heterogeneity of 
variance. For the current set of variables (158, i.e. 79 for males and 79 for females) 13 variables (8%) 
showed non-normality of ANOVA residuals in a Shapiro-Wilks test at the 5% level, while at the 1% 
level only 3 variables were significant in a Shapiro-Wilks test (Appendix 15). In 48 cases the Shapiro-
Wilks test was significant in one or more single dose groups, and 31 variables (15%) showed variance 
heterogeneity in a Bartlett’s or Levene’s test. Among all 632 comparisons the non-parametric 
Wilcoxon’s test resulted in 26 significant differences (4%); note that this tests also requires 
homogeneity of variance. Despite these findings, i.e. non-normality or variance heterogeneity, the 
normal probability plots (Appendix 6) and the plots of residuals versus fitted values (Appendix 7) 
were generally satisfactory. This suggests that parametric t-tests and Dunnett tests can safely be 
applied. 
In this report confidence intervals were also expressed and plotted as Standardised Effect Size (SES), 
see EFSA (2011b), in order to allow a comparison with SES results for the preceding GRACE project 
(Schmidt and Schmidtke 2014, Schmidt et al 2015ab, 2016, 2017, Zeljenková et al 2014, 2016). SES, 
also known as Cohen’s 𝑑𝑑, is often used in meta-analyses to show the results of different variables in 
the same plot. Reporting and graphically displaying effect sizes was described in Schmidt et al (2016) 
as a way ‘to avoid the yes/no decision trap of statistical tests and to illustrate the size of effects in the 
context of biological relevance’. However, in the absence of clear limit values for biological relevance, 
these authors had to build on the arbitrary EFSA example, where effects of ±1 SD were assumed to 
be unlikely to be of toxicological importance. Schmidt et al (2016) already concluded that the pooled 
standard deviation SD of individual measurements ‘is a priori not expected to be directly related to 
biological relevance’, and Schmidt et al (2017) warned that ‘it should therefore be kept in mind that 
future decisions on relevant equivalence limits may influence the equivalence results’. The results of 
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the current G-TwYST study, where 97% of all intervals extended outside the ±1 SD limits, confirms 
the pattern observed in GRACE. Whereas, displaying the confidence intervals indeed gives a richer 
view on the results than just reporting yes/no decisions, the scale of the SES plots does not seem the 
best choice for equivalence assessments. As Hong et al (2017) remark, the value of SES to support 
data interpretation is limited. Alternatively scaled effect sizes, such as those presented in section 4.1 
(Figure 5 - Figure 8) can be preferred, because the scaling factor (the equivalence limit) is based on 
data analysis of in this case historical data, rather than being an arbitrary value. It can be noted, 
however, that this approach was not available for the GRACE project, because of lack of historical 
data in the same test facility. 
Factorial analyses for single variables allowed to consider effects pooled over more than two groups, 
thus providing more powerful tests for main effects in the absence of interaction. However, this 
approach was in the current work restricted to the testing of differences. In principle, it could be 
further developed for the equivalence tests. 
Most statistical analyses in this report have considered variables one by one, collecting the results 
only in a joint table or plot for ease of interpretation. However, toxicologists often stress that effects 
should be judged together. Wherever a prior hypothesis exists that links multiple variables, these 
may sometimes be translated in a function of those variables. For example, there is a biological 
connection between the pancreas and the regulation of glucose, which leads to a prior expectation 
of a negative correlation between pancreas weight and serum glucose. It may then be sensible to 
perform difference and equivalence testing for an additional variable such as the ratio or log-ratio of 
these variables. Such ratios have not been defined in the current study. 
Another tool to study variables together is pairwise plotting of results per experimental unit. In 
section 4.6 (Figure 25 - Figure 28) this was done for three variables related to liver damage and three 
variables related to kidney damage. The rationale was that correlations between variables would 
show up in these plots, but this was hardly observed in these cases. To assist in the interpretation, 
the effects were plotted together with proposed target effect sizes. Most effects were below these 
limits also at the cage level (as was already observed for the means in section 4.2). We may conclude 
that correlations between these variables related to the same organ are nevertheless not prominent 
as long as the effects are within the targeted range. Of course, correlations could be (and are 
expected to be) more evident for effect sizes that would exceed the limits by large amounts. 
A more detailed approach to testing than reported here would also be possible based on a more 
detailed consultation with toxicologists. For example, nephrotoxic effects can lead to decreased or 
increased kidney weights. However, in both of these cases, the toxicologists would expect to see 
increased urea (Urea) and/or creatinine (Crea) levels. In addition, there might be a decreased level of 
glucose in the urine (Glu) or an increased level of amino acids, but these effects are less predictable. 
Increases in Urea or Crea may indicate nephrotoxic effects that are not yet discernible as deviating 
kidney weights. It is concluded that increased Urea and/or Crea levels are the primary indicators of 
kidney damage, and only increased levels represent a toxicological concern. Considering observed 
normal ranges, an increase by 50% in at least one of the two key variables could be seen as 
potentially concerning, and provide a level to be used as equivalence limit. Specific hypotheses to be 
tested for the differences Δ (on the log scale) between the treatment groups (GM vs. comparator) 
would then be as follows. 
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Difference tests:  
 𝐻𝐻0:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈) = 0 vs. 𝐻𝐻1:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈) > 0 
 𝐻𝐻0:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈) = 0 vs. 𝐻𝐻1:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈) > 0 
Equivalence tests:  
 𝐻𝐻0:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈) = 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈 vs 𝐻𝐻1:   𝐸𝐸(Δ𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈) < 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈 
 𝐻𝐻0:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈) = 𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈 vs. 𝐻𝐻1:   𝐸𝐸(Δ𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈) < 𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈 
where 𝐸𝐸𝐿𝐿𝑈𝑈𝑈𝑈𝑊𝑊𝑈𝑈 =  𝐸𝐸𝐿𝐿𝐶𝐶𝑈𝑈𝑊𝑊𝑈𝑈 = log (1.5). 
In cases when a difference is found or an equivalence cannot be shown, the other variables (kidney 
weight, Glu, amino acids) may provide further interpretation to the toxicologist. These variables are 
therefore considered as secondary: the results can be summarised in terms of absolute values and 
confidence intervals for Δ (also shown graphically), but they would not be part of the testing 
framework based on primary variables. However, fine-tuning of statistical analyses as suggested here 
demands a large investment of time from both toxicologists and statisticians, and it will be very 
difficult to perform such exercises across the whole spectrum of endpoints. 
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